US20210283323A1 - Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome - Google Patents
Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome Download PDFInfo
- Publication number
- US20210283323A1 US20210283323A1 US17/136,377 US202017136377A US2021283323A1 US 20210283323 A1 US20210283323 A1 US 20210283323A1 US 202017136377 A US202017136377 A US 202017136377A US 2021283323 A1 US2021283323 A1 US 2021283323A1
- Authority
- US
- United States
- Prior art keywords
- blood
- filter
- subject
- passing
- components
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 152
- 239000008280 blood Substances 0.000 title claims abstract description 152
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 40
- 239000000090 biomarker Substances 0.000 title abstract description 9
- 230000002757 inflammatory effect Effects 0.000 title abstract description 4
- 238000001914 filtration Methods 0.000 title description 36
- 238000000034 method Methods 0.000 claims abstract description 78
- 239000012503 blood component Substances 0.000 claims abstract description 69
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 34
- 102000004127 Cytokines Human genes 0.000 claims abstract description 32
- 108090000695 Cytokines Proteins 0.000 claims abstract description 32
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 31
- 230000017531 blood circulation Effects 0.000 claims description 29
- 208000010496 Heart Arrest Diseases 0.000 claims description 26
- 108090001005 Interleukin-6 Proteins 0.000 claims description 22
- 230000001939 inductive effect Effects 0.000 claims description 22
- 230000002631 hypothermal effect Effects 0.000 claims description 21
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 17
- 239000000306 component Substances 0.000 claims description 14
- 229910052742 iron Inorganic materials 0.000 claims description 11
- 208000028867 ischemia Diseases 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 7
- 230000004064 dysfunction Effects 0.000 claims description 7
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 6
- 102100032752 C-reactive protein Human genes 0.000 claims description 6
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 claims description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 6
- 102000003945 NF-kappa B Human genes 0.000 claims description 6
- 108010057466 NF-kappa B Proteins 0.000 claims description 6
- 230000027455 binding Effects 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000002737 Heme Oxygenase-1 Human genes 0.000 claims description 5
- 108010018924 Heme Oxygenase-1 Proteins 0.000 claims description 5
- 108010063738 Interleukins Proteins 0.000 claims description 5
- 102000015696 Interleukins Human genes 0.000 claims description 5
- 239000000017 hydrogel Substances 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 229940047122 interleukins Drugs 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 5
- 230000010410 reperfusion Effects 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 230000000717 retained effect Effects 0.000 claims description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 4
- 108090000978 Interleukin-4 Proteins 0.000 claims description 4
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims description 4
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 208000029028 brain injury Diseases 0.000 claims description 4
- 230000002107 myocardial effect Effects 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 3
- 101000599858 Homo sapiens Intercellular adhesion molecule 2 Proteins 0.000 claims description 3
- 101000599868 Homo sapiens Intercellular adhesion molecule 4 Proteins 0.000 claims description 3
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 claims description 3
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 3
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 claims description 3
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 claims description 3
- 102100037874 Intercellular adhesion molecule 4 Human genes 0.000 claims description 3
- 102000008070 Interferon-gamma Human genes 0.000 claims description 3
- 108010074328 Interferon-gamma Proteins 0.000 claims description 3
- 108090000174 Interleukin-10 Proteins 0.000 claims description 3
- 108090000172 Interleukin-15 Proteins 0.000 claims description 3
- 108010002350 Interleukin-2 Proteins 0.000 claims description 3
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 3
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 3
- 102100029064 Serine/threonine-protein kinase WNK1 Human genes 0.000 claims description 3
- 101710124574 Synaptotagmin-1 Proteins 0.000 claims description 3
- 229960003130 interferon gamma Drugs 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000005156 Dehydration Diseases 0.000 claims description 2
- 208000032843 Hemorrhage Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- 230000002085 persistent effect Effects 0.000 claims description 2
- 230000001706 oxygenating effect Effects 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 102100034613 Annexin A2 Human genes 0.000 claims 1
- 108090000668 Annexin A2 Proteins 0.000 claims 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 claims 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 claims 1
- 230000021164 cell adhesion Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 238000005086 pumping Methods 0.000 claims 1
- 210000005167 vascular cell Anatomy 0.000 claims 1
- 239000000463 material Substances 0.000 description 25
- 238000011282 treatment Methods 0.000 description 24
- 230000004087 circulation Effects 0.000 description 17
- 239000000126 substance Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 9
- 230000036470 plasma concentration Effects 0.000 description 9
- 230000002269 spontaneous effect Effects 0.000 description 9
- 238000002615 hemofiltration Methods 0.000 description 8
- 229920002307 Dextran Polymers 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 230000036760 body temperature Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- -1 polyethylene Polymers 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 229940127219 anticoagulant drug Drugs 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000005229 chemical vapour deposition Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 4
- 102000000018 Chemokine CCL2 Human genes 0.000 description 4
- 239000000589 Siderophore Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 230000037452 priming Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000002134 carbon nanofiber Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical class C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 239000002121 nanofiber Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 201000002638 post-cardiac arrest syndrome Diseases 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 238000004381 surface treatment Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000004804 winding Methods 0.000 description 3
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 206010009192 Circulatory collapse Diseases 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 2
- 101000960337 Homo sapiens Intercellular adhesion molecule 5 Proteins 0.000 description 2
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
- 102100039919 Intercellular adhesion molecule 5 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 238000011975 continuous veno-venous hemodiafiltration Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000012959 renal replacement therapy Methods 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010001382 Adrenal suppression Diseases 0.000 description 1
- 206010002941 Apallic syndrome Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000007204 Brain death Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000008039 Secondary Parkinson Disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical class OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000010456 cerebrovascular autoregulation Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000004388 gamma ray sterilization Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 230000010438 iron metabolism Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000008383 multiple organ dysfunction Effects 0.000 description 1
- 208000002089 myocardial stunning Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000005026 persistent vegetative state Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000013310 pig model Methods 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002321 radial artery Anatomy 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000024833 regulation of cytokine production Effects 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3627—Degassing devices; Buffer reservoirs; Drip chambers; Blood filters
- A61M1/3633—Blood component filters, e.g. leukocyte filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/26—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes and internal elements which are moving
- A61M1/262—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes and internal elements which are moving rotating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0238—General characteristics of the apparatus characterised by a particular materials the material being a coating or protective layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
- A61M2205/505—Touch-screens; Virtual keyboard or keypads; Virtual buttons; Soft keys; Mouse touches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/70—General characteristics of the apparatus with testing or calibration facilities
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/75—General characteristics of the apparatus with filters
Definitions
- the invention relates to methods of treating or preventing post-resuscitation syndrome (PRS) comprising filtering or removing inflammatory biomarkers and/or other blood components from a subject.
- PRS post-resuscitation syndrome
- the invention also relates to a therapeutic device for treating post-resuscitation syndrome.
- PRS Post-resuscitation syndrome
- PRS Post-resuscitation syndrome
- PRS includes the following pathophysiological processes: (1) post-cardiac arrest brain injury, (2) post-cardiac arrest myocardial dysfunction, and (3) systemic ischemia/reperfusion response. (Nolan et al., Resuscitation 79:350-379, 2008). Of course, the syndrome is generally further complicated by the original pathological factors that lead to the initiating cardiac arrest (Nolan et al., Resuscitation 79:350-379, 2008).
- Post-cardiac arrest brain injury may result in impaired cerebrovascular autoregulation, cerebral edema, and/or post-ischemic neurodegeneration.
- Clinical manifestations include coma, seizures, myoclonus, cognitive dysfunction, persistent vegetative state, secondary Parkinsonism, cortical stroke, spinal stroke, and brain death (Nolan et al., Resuscitation 79:350-379, 2008).
- Post-cardiac arrest myocardial dysfunction may result in global hypokinesis (myocardial stunning), reduced cardiac output, and acute coronary syndrome.
- Clinical manifestations include early revascularization of acute myocardial infarction, hypotension, dysrhythmias, and cardiovascular collapse (Nolan et al., Resuscitation 79:350-379, 2008).
- Systemic ischemia/reperfusion response may result in systemic inflammatory response syndrome, impaired vasoregulation, increased coagulation and/or coagulation abnormalities, adrenal suppression and/or dysfunction, impaired tissue oxygen delivery and utilization, and impaired resistance to infection.
- Clinical manifestations include ongoing tissue hypoxia/ischemia, hypotension, cardiovascular collapse, pyrexia (fever), hyperglycemia, multi-organ failure, and infection (Nolan et al., Resuscitation 79:350-379, 2008).
- PRS has also been associated with complement activation, improper regulation of cytokine production by leukocytes, expression of adhesion molecules, cytokine release, and endotoxin presence in plasma (Laurent et al., J. Am. Coll. Cardiol. 46(3):432-37, 2005; and Adrie et al., Curr. Opin. Crit. Care 10:208-212, 2004, which is incorporated herein by reference in its entirety).
- PRS is characterized by a large inflammatory response that has been linked to increased oxidative stress which can lead to nerve cell malfunction or death and subsequently poor outcomes for patients.
- the release of oxygen free radicals, coagulation factors, complement-activation products, and cytokines may occur during revascularization after ischemia (reperfusion syndrome).
- Previous studies have shown that non-survivors of cardiac arrest have a significantly greater escalation of these pro-inflammatory biomarkers as compared to survivors (Adrie et al., Circulation 106:562-568, 2002; Sipos et al., Resuscitation 81:603-608, 2010, which documents are incorporated by reference herein in their entireties).
- the release of these factors leads to marked activation of neutrophils with up-regulation of their surface adhesion molecules (Adrie et al., Curr. Opin. Crit. Care 10:208-212, 2004).
- the resulting leukocyte adhesion is an important step in vascular endothelium injury, leading to increased microvascular permeability and thrombosis. Id.
- the elevation of circulating pro-inflammatory as well as immunomodulatory cytokines and adhesion molecules is a feature of PRS, which mimics the immunological disorders observed in sepsis.
- PRS treatment is time sensitive, and care of PRS patients must accommodate a range of patients, for example, patients who are hemodynamically stable as well as unstable and/or comatose patients.
- the phases of PRS/post-cardiac arrest syndrome may be categorized as set forth in the following table:
- Therapeutic hypothermia after ventricular fibrillation cardiac arrest improves neurologic outcome and has been recommended for post-resuscitation care.
- Therapeutic hypothermia was thought to benefit patients because the cooling of the body would reduce the amount of the pro-inflammatory substances circulating in the cardiovascular system.
- a recent study in a pig model of cardiac arrest with hypothermia indicates that the inflammatory response still occurs (with corresponding upregulation of markers of systemic inflammation) even when the animals were cooled as early as possible during the arrest (Sipos et al., Resuscitation 81:603-608, 2010).
- cytokines and soluble receptors occur in the bloodstream as early as 3 hours after cardiac arrest.
- cytokines, including IL-6 show greater elevation in nonsurvivors than in survivors as well as in patients requiring vasopressor therapy compared with other patients (Adrie et al., Curr. Opin. Crit. Care 10:208-212, 2004).
- cytokines and other blood components may be difficult to remove from the blood, especially in a short period of time following loss of circulation/cardiac arrest.
- cytokines and other toxins are often bound to the blood protein albumin, and conventional dialysis membranes do not remove substantial quantities of these protein-bound toxins from the blood. This is because protein-impermeable membranes are generally used in dialysis methods. Consequently, extracorporeal circuits such as continuous renal replacement therapies (CRRT), coupled plasma filtration adsorption (CPFA) and continuous veno-venous hemodiafiltration (CVVHDF) have been developed to minimize cell-associated cytokine concentrations in the blood of septic patients. However, most extracorporeal circuits to date function primarily as artificial kidneys or perfusion devices.
- CRRT continuous renal replacement therapies
- CPFA coupled plasma filtration adsorption
- CVVHDF continuous veno-venous hemodiafiltration
- a therapeutic device comprising tubing; at least one pump; and a column or filter configured to selectively remove leukocytes, cytokines, and/or other blood components from the blood of a patient having or at recognized risk of having PRS at a blood flow rate through the filter or column of at least 2.5 L per hour to effectively treat or prevent PRS.
- the therapeutic device may optionally comprise a blood temperature regulator.
- a device comprising a column or filter that is capable of removing interleukins, tumor necrosis factor ⁇ (TNF- ⁇ ), c-reactive protein (CRP), nuclear factor-kappa B (NF- ⁇ B) subunit p65, interferon- ⁇ , elastase, inducible NO synthase, heme oxygenase-1, free radicals, intracellular adhesion molecules, vascular cell adhesion molecule-1, complement components, granulocyte-macrophage colony-stimulating factor (GM-CSF), monocyte chemoattractant protein-1 (MCP-1), Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) protein, and/or von Willibrand factor (VWF).
- TNF- ⁇ tumor necrosis factor ⁇
- CRP c-reactive protein
- NF- ⁇ B nuclear factor-kappa B subunit p65
- interferon- ⁇ elastase
- the interleukins include, for example, IL-1 ⁇ , IL-2, IL-4, IL-6, IL-10, and IL-15.
- the intracellular adhesion molecules include ICAM1, ICAM2, ICAM3, ICAM4, and ICAM5.
- the free radicals are not limited and may be, for example, free iron radicals or free oxygen radicals.
- the complement components include, for example, C3a and terminal complement complex (TCC).
- the device may selectively remove IL-6.
- the device may be portable.
- the device may be configured for a blood filtration rate of 2.5-5 L/hr.
- the filter or column comprises a hydrogel layer to which one or more molecules capable of selectively binding leukocytes, cytokines, and/or other blood components has been immobilized.
- the hydrogel comprises dextran.
- the invention also provides a therapeutic device as described above which comprises a surface treatment filter.
- a therapeutic device comprising tubing, at least one pump, a blood temperature regulator, and a column or filter, wherein the device is capable of detecting the presence and/or amount of soluble PRS-inducing or -exacerbating blood components, and selectively removing or partially removing one or more of the detected blood components from the blood of a subject.
- the invention also provides such a device further comprising one or more of an air-free pressure chamber, a pressure sensor, an oxygenator, a blood leak detector, an air detector, a cooler, a heater, an LED touch screen, and/or a battery.
- the LED touch screen displays information relating to the nature and/or amount of one or more PRS-inducing or -exacerbating blood components in the blood to be filtered.
- the LED touch screen may display information relating to IL-6 plasma concentration levels.
- the device may also be configured to detect and display information about the nature and/or amount of the one or more PRS-inducing or -exacerbating blood components in the blood to be filtered within about 45 minutes or less after filtration has started.
- the device may also be configured to detect and display information about the nature and/or amount of the one or more PRS-inducing or -exacerbating blood components in the blood to be filtered in 30 minute intervals and to adjust flow rate through the filter or column based on the information.
- the device may be configured to increase flow rate through the filter or column when IL-6 plasma concentration levels are detected above 200 ⁇ g/L after 45-75 minutes after filtering with the device.
- LED touch screen displays information relating to the nature and/or amount of one or more PRS-inducing or -exacerbating blood components in the blood post-filtration.
- a device as described above, which adjusts flow rate through the filter or column to maintain IL-6 plasma concentration levels below 200 ⁇ g/L in post-filtration blood.
- the therapeutic device of the present invention may be configured to induce therapeutic hypothermia in the subject.
- the device of the present invention may also be configured for automated plasma recovery and pressure-driven automatic flow control.
- the filter or column may be present as part of a detachable filtration module.
- the detachable module may be exchanged or selected for insertion in the device depending upon the blood component or blood components to be removed.
- a therapeutic device for filtering blood comprising a pump, and a filtering module comprising one or more cylinders and filter material on at least a partial inner surface of the one or more cylinders, the therapeutic device being configured to send blood into and/or through the one or more cylinders along a spiral path such that blood components that induce or exacerbate PRS in a subject, or a portion thereof, are selectively retained in the one or more cylinders.
- a device may for example, slowly inject blood in an upward direction combined with a fast rotary motion to exert a centrifugal force on the blood sent into and/or through the one or more cylinders, such that one or more of the blood components that induce or exacerbate PRS in a subject contact the filter material.
- the therapeutic device may be configured to obtain a centrifugal force within the one or more cylinders of 10,000 to 100,000 G.
- a spiral-wound filter is constructed to provide a compact filter with a large surface area over which the blood is flowed.
- the filter is made up of an outer housing in which the blood is contained, composed of a cylinder side wall and two end caps ( FIG. 5A ). Inside the housing is the filter element ( FIG. 5B ), whose filter inlet port and exhaust port protrude through the walls of the end caps via sealed holes. The blood flows in a spiral fashion from the fluid inlet port into the inner tube then into the spiral space via the inlet exhaust ports.
- the filter element is a laminate structure of a substantially impermeable, flexible but semi-rigid substrate support layer, of a relatively blood-inert composition such as polyethylene or cellulose. Laminated to that surface is the active surface matrix, in some cases made of carboxymethyl dextran to which molecules can be covalently attached using well-defined chemistries (see Lofas S, Johnsson B, J. Chem. Soc. Chem.
- the dextran layer creates a suspended hydrogel that is conducive to adhering blood agents.
- the carboxymethyl dextran minimizes nonspecific binding of biomolecules to the surface and increases the binding capacity of the surface.
- the surface chemistry of the dextran may be modified to provide a surface with altered properties such as hydrophobic, lipophylic, or lower charge.
- a pliant over-molded sealing and spacing ridge is over-molded onto the perimeter of the laminate structure such that when it is wound around the inner tube, it provides multiple sealing functions: 1) it seals against the inner tube; 2) it seals against the adjoining layers at the two ends so that blood fluid is forced to flow only spirally; 3) it seals against the outer tube; and when the filter element is placed into the cylinder side wall and the two end caps are placed and compressed into position before being glued or ultrasonically welded to the cylinder side wall, they seal against the end caps and side wall.
- the surface is functionalized to adhere to PRS-inducing or -exacerbating blood components.
- PRS-inducing or -exacerbating blood components For instance, for IL-8 specific adhesion, “two monoclonal antibodies recognizing different epitopes of IL-8” may be used.
- MAB208 is a mouse immunoglobulin G 1 (IgG 1 ) that was raised against human IL-8 and then protein G column purified from mouse ascites fluid by R & D Systems (Clone No. 6217.111; Cat. No. MAB208).
- JK8-2 is a mouse IgG1 that was raised against human IL-8 and produced by Biolegend (San Diego, Calif.; Clone No.
- JK8-2 The protein G affinity chromatography and then biotinylated.
- size-exclusion chromatography As a polishing step, size-exclusion chromatography (Amersham FPLC with a Superdex-200 gel filtration column) was applied by our laboratory to eliminate traces of other proteins such as albumin from both monoclonal antibodies.
- the antibody fractions were collected in HBS-EP buffer and concentrated with Amicon Ultra Centrifugal Filter Devices (10 kDa) from Millipore (Billerica, Mass.; Product No. UFC901024). The purity was determined by SDS-PAGE and MALDI-TOF mass spectroscopy.
- concentrations were measured using a Micro BCA Protein Assay Kit from Pierce (Rockford, Ill.; Cat. No. 23235).” Id. Other monoclonal antibodies may be used to bind to one or more of these PRS-inducing or -exacerbating blood components.
- the surface matrix may be functionalized to adhere to free iron in the bloodstream.
- Free iron typically in the form of Fe 3+
- Siderophores are iron-complexing compounds of low molecular weight that are synthesized by bacteria and fungi, and serve to deliver the iron to the microbes. Ferriooxamine is one example. Siderophores are classified into five principal groups according to their chemical structures: hydroxamates, catecholates, carboxylates, heterocyclic compounds, and mixed types. All the natural siderophores are designed to chelate (adhere to) Fe(III) selectively (Reference: Inorganic Biochemistry of Iron Metabolism, Robert Crichton, 2001, Wiley and Sons).
- the blood is circulated in the spiral fashion in the spiral space of the filter element, flowing outwardly until it reaches the exit intake ports of the outer tube, through which the blood exits into the outer tube and finally out the exhaust port.
- the device may employ pressure at the inlet port as well as negative pressures at the exhaust port.
- the filter may be alternatively configured to have the blood flow spirally inward toward the central tube, in which case the center tube becomes the exhaust port and the outer tube becomes the intake port.
- the surface matrix may be composed of alternative materials such as spun polyethylene teraphthalate (PET), cellulose acetate, polyurethanes, nylon, polyacrylonitrile or polypropylene.
- the semi-rigid substrate may be formed into the cylindrical spiral shape by creating features on the inner tube that the over-molded ridge to which the in-most edge of the semi-rigid substrate is affixed and then winding the semi-rigid substrate around the inner tube as a mandrel.
- the semi-rigid material may be a polymer that can be thermoformed and the material can be heated to soften it while the winding is occurring.
- the inner mating surface of the end caps into which the filter element seats may be conically shaped so that when all the components are pressed together for the final assembly, the inner wall of the end caps press inward on the over-molded sealing edge at the top and bottom of the filter element, thus sealing the end-surfaces of the filter element.
- the ends of the filter element may also be sealed with a non-bioactive sealing agent like silicone.
- the flexible semi-rigid support layer should have both a smooth surface and preferably a surface that may be treated with a material of low binding force to the blood so that it is conducive for maximal laminar flow along the surface of the semi-rigid support layer.
- the surface matrix will be roughened which will result in turbulent, non-laminar flow along its surface.
- a filter or column comprising a filter material capable of removing leukocytes and/or soluble blood components from the blood of a subject having or at recognized risk of having PRS at a blood flow rate through the filter of at least 2.5 L per hour to effectively treat or prevent PRS.
- the filter or column may selectively remove cytokines from the blood.
- a system for determining a treatment procedure for a subject having or at recognized risk of having PRS comprising a module for obtaining a blood sample from the subject; a module for measuring and/or identifying the presence, absence, or amount of one or more biomarkers present in the blood of the subject after cardiac arrest, ischemia or other loss of circulation; a module and LED screen capable of determining and displaying a treatment procedure for the subject based on the presence, absence, or amount of the measured and/or identified one or more biomarkers; and an adjustable filter module.
- the present invention also provides a method of treating or preventing PRS comprising filtering blood of a subject having or at recognized risk of having PRS with a device a described above.
- a method of treating or preventing PRS comprising passing the blood of a subject at risk of PRS through a device configured to remove leukocytes, cytokines, free radicals, von Willibrand factor, and/or other blood components at a flow rate of at least 2.5 L per hour to effectively treat or prevent PRS.
- an anticoagulant, a chelating agent, and/or a glucocorticoid is added to the blood as it passes through the device.
- the anticoagulant may be Anticoagulant Citrate Dextrose Solution A (ACD-A) or heparin.
- the device is configured for extracorporeal blood circulation.
- the method may comprise filtering the blood extracorporeally to remove leukocytes.
- the leukocytes to be removed may be lymphocytes, granulocytes and/or monocytes.
- the method comprises partial removal of peripheral neutrophils.
- There is also provided a method of treating or preventing PRS comprising inducing hypothermia in a subject at risk of PRS, and passing blood of a subject at risk of PRS through a device as described above.
- a cylindrical filter element comprising a surface activated fiber sheet and a substrate support that form a layer, the layer wound in a spiral about an inner tube; and a space adjacent to at least a partial surface of the fiber sheet, the filter element being configured to accommodate blood flow in a spiral path and to allow blood to come into contact with the fiber sheet such that blood components that induce or exacerbate PRS in a subject, or a portion thereof, are selectively retained in the filter element.
- a cylindrical filter element may comprise a flexible semi-rigid support layer having a smooth surface and a surface treated with a material of low binding force in the blood.
- such a cylindrical filter element may comprise a roughened surface matrix for turbulent, non-laminar flow along its surface.
- a therapeutic device comprising a filter element comprising a surface activated filtering agent that attracts free iron, and which is configured to selectively remove the free iron from the blood of a patient having or at recognized risk of having PRS at a blood flow rate through the filter element of at least 2.5 L per hour to effectively treat or prevent PRS.
- a filter element comprising a filter material having an enhanced surface area for efficient and selective removal of one or more PRS-inducing or -exacerbating blood components from the blood of a patient having or at recognized risk of having PRS at a blood flow rate through the filter element of at least 2.5 L per hour to effectively treat or prevent PRS.
- the filter element may comprise carbon nanofibers or sintered nanoparticles.
- the surface area of the filter material may be enhanced by chemical vapor deposition.
- a method of making a filter element with an enhanced surface area comprising obtaining a filter material capable of removing leukocytes and/or soluble blood components from the blood of a subject having or at recognized risk of having PRS at a blood flow rate through the filter element of at least 2.5 L per hour to effectively treat or prevent PRS, and coupling nanofibers to the filter material or sintering nanoparticles to the filter material.
- a method of making a filter element with an enhanced surface area comprising obtaining a filter material capable of removing leukocytes and/or soluble blood components from the blood of a subject having or at recognized risk of having PRS at a blood flow rate through the filter element of at least 2.5 L per hour to effectively treat or prevent PRS, and exposing the filter material to chemical vapor deposition.
- FIG. 1 shows a portable device capable of removing leukocytes, cytokines, and/or other blood components from the blood of a patient to effectively treat post-resuscitation syndrome.
- FIG. 2 shows a cylindrical column for filtering blood of a subject that has or is at risk of having post-resuscitation syndrome.
- FIG. 3A shows a filter module for filtering blood of a subject that has or is at risk of having post-resuscitation syndrome.
- FIG. 3B shows three possible membranes that may be included in the filter module for removing one or more types of cells and/or other blood components.
- FIG. 4A provides a partial view of a conical-shaped cylinder having an inner surface comprising a membrane filter or surface treatment filter.
- FIG. 4B shows a detachable filter module comprising multiple conical-shaped filters, housing for the filters, and a base.
- FIG. 5A shows the outer housing for a filter element.
- FIG. 5B shows a filter element, which may be placed in an outer housing.
- FIG. 6 shows extracorporeal filtration of IL-6 from a subject.
- FIG. 7 shows a flow diagram for one possible course of treatment or prevention for post-resuscitation syndrome with a device capable of achieving a blood flow rate of at least 2.5 L/h.
- FIG. 8 shows a flow diagram for one possible method for determining a treatment course for post-resuscitation syndrome.
- cytokine As used herein, the singular forms “a,” “an,” and “the” include the plural reference unless the context clearly dictates otherwise. For example, reference to “a cytokine” would also mean that mixtures of one or more cytokines can be present unless specifically excluded.
- a device as invented by the inventors may comprise tubing, at least one pump, and a column or filter capable of selectively removing leukocytes, cytokines, and/or other blood components from the blood of a patient having or at recognized risk of having post-resuscitation syndrome (PRS) to effectively treat or prevent post-resuscitation syndrome.
- the device may be therapeutic and may function as a device to treat or prevent post-resuscitation syndrome and/or one or more symptoms of post-resuscitation syndrome.
- the device may be capable of inducing hypothermia in a subject, pump and receive blood from a subject, pump blood from a subject through one or more filter modules, filter blood of a subject to remove toxic substances that cause or exacerbate post-resuscitation syndrome, and/or return the blood of a subject to the subject.
- the device may function to pump blood extracorporeally, for filtration, heating or cooling, or other treatment.
- a therapeutic device comprising tubing, at least one pump, a blood temperature regulator, and a column or filter, wherein the device is capable of detecting the presence and/or amount of soluble PRS-inducing or -exacerbating blood components, and selectively removing or partially removing one or more of the detected blood components from the blood of a subject.
- a therapeutic device comprising a pump, and a filtering module comprising one or more cylinders and filter material on at least a partial inner surface of the one or more cylinders, the therapeutic device being configured to send blood into and/or through the one or more cylinders along a spiral path such that blood components that induce or exacerbate PRS in a subject, or a portion thereof, are selectively retained in the one or more cylinders.
- centrifugal force is exerted on the blood sent into and/or through the one or more cylinders, such that one or more of the blood components that induce or exacerbate PRS in a subject contact the filter material.
- the device may, for example, slowly inject blood in an upward direction and simultaneously rotate the fluid contents to exert a centrifugal force on the blood sent into and/or through the one or more cylinders.
- the blood contacts the filter material on the inner surface of one or more cylinders and substances that induce or exacerbate PRS are selectively retained while the filtration product returns to the base of the filtration module via gravity, where it may be further circulated back to the subject.
- the centrifugal force within one or more cylinders of the device may be 10,000 to 100,000 G; 20,000-80,000 G, 25,000-75,000 G, or 50,000 G.
- a device comprising tubing, at least one pump, a blood temperature regulator, and a detachable module capable of removing leukocytes, cytokines, and/or other blood components from the blood of a patient to effectively treat or prevent post-resuscitation syndrome.
- the detachable module selectively removes cytokines up-regulated during post-resuscitation syndrome.
- the detachable module selectively removes free iron radicals.
- the detachable module may be exchanged or selected for insertion in the device depending upon the blood component to be removed.
- a cassette tubing system and slide stator pumps may be included and preparation time of the tubing may thereby be reduced.
- Arterial and venous tubing may be loaded simultaneously, and the use of cassette tubing allows for correct position of air detectors.
- the slide stator pumps also provide for tubing set up without winding.
- a device as provided herein may be capable of therapeutic apheresis and/or continuous renal replacement therapy.
- the device may, for example, be capable of automated plasma recovery and/or may have pressure driven automatic flow control.
- the device may be capable of automatic priming and thereby reduced priming time compared to conventional devices. Reduced priming volumes and increased safety may also be achieved by automatic priming.
- the device may be high-volume hemofiltration device.
- the device may achieve blood flow rates of, for example, 1-400 mL/min.
- the device may be capable of blood flow rates of 200-400, 300-375, or 350 mL/min.
- the device is configured to increase flow rate through the filter or column when IL-6 plasma concentration levels, or when the levels of a different cytokine or blood component, are detected above 200 ⁇ g/L.
- the plasma concentration levels are not particularly limited. For example, if IL-6 plasma concentration levels in a subject are above 150-500 ⁇ g/L, the device may detect such concentration and adjust the flow rate through the filter or column accordingly. The device may also adjust flow rate through the filter or column to maintain plasma concentration levels of a PRS-inducing or -exacerbating blood component below a certain toxic threshold. For example, the device may be configured to adjust flow rate through the filter or column to maintain IL-6 plasma concentration levels below 150, 175, 190, 200, 210, or 250 ⁇ g/L in post-filtration blood.
- the device may obtain measurements of blood component levels at any time, including, for example, 45 min, 50 min, 60 min, 65 min, 70 min, or 75 min after collecting a sample from the subject at risk of having or having post-resuscitation syndrome.
- the device may be further configured to detect levels of blood components such as cytokines, free radicals, etc., at intervals of 10 min, 15 min, 20 min, 30 min., 45 min, and so on.
- the device of the present invention will be capable of a range of blood filtration rates as well.
- the blood filtration rate of the device as described herein may achieve a blood filtration rate of 0.9 to 10 L/h, 1 to 9 L/h, 2 to 8 L/h, 2.5 to 5 L/h, 3, 4, 6, or 7 L/h.
- the device may be configured for extracorporeal circulation.
- the device may be stationary or portable.
- the portable device may, for example, have wheels, and/or be of light weight and compact, such that it may be conveniently carried, transported, or rolled to a patient at risk of post-resuscitation syndrome.
- the filter of the device is not particularly limited, and may be, for example, selected from commercially available filters, etc.
- the filter may be, for example, a leukocyte removing filter as described in U.S. Pat. Nos. 8,496,833; 7,641,794; and 7,655,146, each of which is incorporated by reference herein in its entirety.
- the filter may be a surface treatment filter.
- the column of the device is not particularly limited, and may be a leukocytapheresis column or a commercially available column capable of removing leukocytes.
- the filter or column may be selected based on the nature and/or amount of blood components to be removed and/or reduced.
- Filters and columns of the invention may remove leukocytes, cytokines, and/or other blood components from the blood of a patient to effectively treat or prevent post-resuscitation syndrome.
- Leukocytes to be removed include, for example, granulocytes (e.g., neutrophils, eosinophils, or basophils), macrophages, monocytes, and/or lymphocytes (e.g., B cells and T cells).
- Filters and columns of the invention may remove all cells of a certain type or a partial amount.
- the filters and/or columns of the invention may partially remove peripheral neutrophils from the blood of subject having or at risk of having PRS.
- filters and columns of the invention may remove all cytokines of a certain type or just a partial amount or a percentage of one or more types of cytokine. Cytokines to be removed include any of the cytokines described herein.
- the filter or column may be configured to reduce soluble IL-6 levels in the blood of a subject by 90%, 75%, 60%, 50%, 40%, etc.
- the column or filter may also be configured to selectively remove free iron, free iron radicals, complement components, von Willebrand factor, free oxygen radicals, etc.
- the column or filter may have a volume of 25-500 mL, 50-300 mL, 100-200 mL, 125-175 mL or 150 mL, and may be in the shape or a cylinder or cone.
- the column or filter may be 50-600 mm in height, 75-500 mm in height, 100-400 mm in height, 125-350 mm in height, 150-300 mm in height, 175-250 mm in height, 200-225 mm in height, 550, 450, or 375 mm in height.
- the device may comprise multiple conical-shaped filters or membranes which selectively retain or exclude blood components based on size, binding capacity of the filter or membrane, or specificity with regard to, for example, cell type, protein charge, or amino acid sequence.
- the column may be 10-220 mm, 20-200 mm, 30-180 mm, 40-160 mm, 50-150 mm, 75-100 mm, 60, 70, 80, 90, 110, 120, 130, 140, 170, or 190 mm in diameter.
- the column or filter may comprise nonwoven fabric, such as nonwoven fabric comprising polyethylene terephthalate.
- nonwoven fabric comprising polyethylene terephthalate.
- other materials which may used as part of the column or filter include hydrogels, dextran (e.g., carboxymethyl dextran), cellulose, gold, or glass.
- the materials may be used alone or in combination.
- the column or filter may comprise material capable of removing leukocytes and/or soluble blood components from the blood of a subject having or at recognized risk of having PRS at a blood flow rate through the filter of at least 2.5 L per hour to effectively treat or prevent PRS.
- the material may be such that is capable of, for example, selectively and simultaneously removing 1, 2, 3 or more blood components from the blood of a subject having or at recognized risk of having PRS at a blood flow rate through the filter of at least 1.0 L, 1.5 L, 2.0 L, 2.5 L, 3.0 L, 3.5 L, 4.0 L, 4.5 L, 5.0 L, 10 L or more per hour.
- the column or filter may comprise an enhanced surface area or an enhanced area to dimension ratio.
- a surface activated filtering agent present in the filter or column may enhance the chemical attraction of the filter or column material to one or more compounds.
- the surface area of the column or filter may be enhanced by nanofibers such as carbon nanofibers that are coupled to the surface. The high surface area, low density, and high pore volume of such nanofibers increase the functional filtration surface area of the column or filter.
- the surface area of the filter may also be enhanced by chemical vapor deposition (CVD).
- CVD chemical vapor deposition
- a filter material such as carbon nanofibers may be exposed to chemical vapor deposition to yield nanofiber-supported nanoparticles.
- the surface area may be enhanced by nanoparticles sintered thereto by any process known to those of skill in the art.
- the blood components may be efficiently and selectively removed from the blood during filtering via such a column or filter having an enhanced surface area.
- the column or filter may selectively remove inflammatory biomarkers from the blood.
- the column or filter may be specifically adapted to selectively remove cytokines from whole blood, either by direct removal of IL-6 or by removal of cells that produce them.
- the column or filter may be specifically adapted to selectively remove IL-6 from whole blood, either by direct removal of IL-6 or by removal of white blood cells that produce IL-6.
- the column or filter may also be configured as a module.
- the module may be detachable.
- the column or filter may be present as part of a detachable filtration module or separately.
- a column for TNF- ⁇ may be detachable such that it may be removed from the device, and a filter or column for removing IL-6 may be inserted in its place.
- the detachable module may be exchanged or selected for insertion in the device depending upon the blood component or blood components to be removed.
- the column or filter is capable of removing toxins and harmful substances associated with post-resuscitation syndrome, including, but not limited to: interleukins (e.g., IL-1 ⁇ , IL-2, IL-4, IL-6, IL-10, and IL-15), tumor necrosis factor ⁇ (TNF- ⁇ ), interferon (e.g., interferon- ⁇ ), c-reactive protein (CRP), nuclear factor-kappa B (NF- ⁇ B) subunit p65, elastase, inducible NO synthase (iNOS), heme oxygenase-1 (HO-1), free radicals (e.g., free iron radicals or free oxygen radicals), intracellular adhesion molecules (e.g., ICAM1, ICAM2, ICAM3, ICAM4, ICAM5), vascular cell adhesion molecule-1, complement components (e.g., terminal complement complex (TCC) or complement components C3a (C3a)), granulocyte-macrophage colon
- the column or filter may also be configured to remove white blood cells (e.g., lymphocytes, macrophages, monocytes, granulocytes), or substances secreted by any such white blood cells, red blood cells, or platelets.
- the filter module or column be configured to specifically remove one substance or molecule from the blood of a subject or configured to remove a combination of the above substances.
- removal of white blood cells may be performed to prevent an increase in the level of products produced or secreted by white blood cells.
- the column, filter, and/or device of the instant invention may be sterilized by any number of methods, e.g., by gamma-ray sterilization, or by contacting the column, filter, and/or device with a sterilization agent, such as alcohol.
- a sterilization agent such as alcohol
- the device may comprise one or more pumps.
- the pump may be any commercially available pump, for example, non-occlusive centrifugal pumps, slide stator pumps, etc.
- the pump may withdraw blood from the patient and transport it through the device.
- the invention provides, for example, a device comprising a pump that transports blood through an extracorporeal circuit or sub-circuit, or an infusion pump that delivers anticoagulants, liquid, solutes, substitute blood components, or other substances and compounds to blood.
- the one or more pumps of the device are not particularly limited.
- the pump may be a belt-driven pump.
- the device may also include a syringe pump, stator pump, or other types of pumps suitable for methods as described herein.
- the pump may also be any pump that provides excellent stability from low to high speeds.
- the tubing may be, for example, arterial and/or venous tubing.
- the tubing may be made of any suitable material including plastic or rubber.
- the device may comprise a blood temperature regulator for activating a heater or cooler.
- the heater may be a resistance heater such as a wire coil.
- the heater may be in the form of a heat-generating surface.
- the cooler may be in the form of a heat-absorbing surface.
- the heat absorbing surface will generally comprise a metal foil wrapped around a catheter, typically having an exposed area of at least about 2 cm 2 .
- the cooler may be a thermoelectric cooler.
- the components of the device, including the blood temperature regulator, cooler, etc. may be configured to induce therapeutic hypothermia in a subject.
- the device may comprise additional components or modules, such as an oxygenator, catheter, blood infuser, temperature sensor, etc.
- the oxygenator provides oxygenated blood to be returned to the patient's arterial system.
- the blood infuser may deliver large volumes of plasma substitute, blood substitute, or whole blood, optionally with preservation and or resuscitation cocktails.
- the device may comprise one or more of an air-free pressure chamber, a pressure sensor, a blood leak detector, an air detector, a scale, an LED touch screen, and/or a battery.
- the air-free pressure chamber may minimize contact between air and blood.
- One or more of the components of the device may be heparin bonded.
- a touch screen may display information relating to the nature and/or amount of one or more PRS-inducing or -exacerbating blood components in the blood to be filtered.
- the touch screen may display information related to, for example, IL-6 plasma concentration levels.
- the device of the present invention may also be configured to detect and display information about the nature and/or amount of the one or more PRS-inducing or -exacerbating blood components in the blood to be filtered within about 45 minutes, 30 minutes, 25 minutes, 20 minutes, 10 minutes, or less after filtration had started.
- a device as provided herein may be, for example, configured to detect and display information about the nature and/or amount of the one or more PRS-inducing or -exacerbating blood components in the blood to be filtered in 30 minute, 25 minute, 20 minute, 15 minute, 5 minutes, or 1 minutes intervals.
- a device as described herein may also adjust flow rates through the filter or column based on the information that is detected and displayed.
- the system may comprise one or more of the following: a module for obtaining a blood sample from the subject; a module for measuring and/or identifying the presence, absence, or amount of one or more biomarkers present in the blood of the subject after cardiac arrest, ischemia or other loss of circulation; a module and LED screen capable of determining and displaying a treatment procedure for the subject based on the presence, absence, or amount of the measured and/or identified one or more biomarkers; and an adjustable filter module.
- the system may be in the form of a kit or other assembly.
- the system may comprise device components as described herein, which components function in the context of the system to assist in effectively treating or preventing PRS.
- the invention provides methods of treating or preventing post-resuscitation syndrome comprising: passing the blood of a subject at risk of post-resuscitation syndrome through a therapeutic device configured to remove leukocytes, cytokines, free radicals, von Willibrand factor, and/or other blood components after cardiac arrest to effectively treat or prevent post-resuscitation syndrome.
- the present invention also provides a method of treating or preventing PRS comprising filtering blood of a subject having or at recognized risk of having PRS with a device a described above.
- a method of treating or preventing post-resuscitation syndrome comprising inducing hypothermia in a subject at risk of post-resuscitation syndrome, and passing blood of the subject at risk of post-resuscitation syndrome through a device comprising tubing, at least one pump, a blood temperature regulator, and a column or filter, the device being capable of detecting the presence and/or amount of soluble PRS-inducing or -exacerbating blood components, and selectively removing or partially removing one or more of the detected blood components from the blood of a subject.
- a method of treating or preventing post-resuscitation syndrome comprising passing the blood of a subject at risk of post-resuscitation syndrome through a device configured to remove leukocytes, cytokines, free radicals, von Willibrand factor, and/or other blood components at a flow rate of at least 2.5 L per hour to effectively treat or prevent post-resuscitation syndrome.
- Methods as described above may also include addition of an anticoagulant, a chelating agent, and/or a glucocorticoid to the blood as it passes through the device.
- the anticoagulant may be Anticoagulant Citrate Dextrose Solution A (ACD-A) or heparin.
- Treatment methods may comprise filtering the blood of a subject having or at recognized risk of having PRS with a device comprising tubing, at least one pump, and a filter or column capable of selective removing leukocytes, cytokines, and/or other blood components from the blood of a patient having or at recognized risk of having PRS at a blood flow rate through the filter of at least 2.5 L per hour to effectively treat or prevent PRS.
- the method may comprise filtering the blood extracorporeally to remove, for example, leukocytes.
- the leukocytes to be removed may be lymphocytes, granulocytes and/or monocytes.
- the method comprises partial removal of leukocytes (e.g., lymphocytes or peripheral neutrophils), or partial removal of one or more cytokines (e.g., IL-4 or IL-6).
- a method of treating or preventing post-resuscitation syndrome comprising inducing hypothermia in a subject at risk of post-resuscitation syndrome, and passing blood of a subject at risk of post-resuscitation syndrome through a device as described above which includes a blood temperature regulator.
- a method of treating children after extracorporeal circulation e.g., for cardiac surgery.
- High volume hemofiltration may be used to filter large quantities of blood rapidly.
- high-volume hemofiltration may be used to achieve 100 L of fully balanced ultrafiltration over an 8-hour period.
- High volume hemofiltration may be performed, for example, at a rate of 180-220 ml/kg/h, 190-210 ml/kg/h, and preferably at 195-205 ml/kg/h.
- high volume hemofiltration may be performed at 200 ml/kg/h for 8 hours.
- High volume hemofiltration may also be performed for 0.5-12 h, 1-10 h, 2-9 h, 3-8 h, 4-6 h, or for 5 h.
- Similar methods of high-volume ultrafiltration are also provided.
- High volume hemofiltration may be performed with or without inducing hypothermia in the subject. Induction of hypothermia may control inflammatory processes and improve recovery and/or survival. Body temperature may be reduced to a desired temperature or range, e.g., 32-36° C., 33-35° C., or 34° C.
- treatment may vary depending upon several factors. Generally the sooner treatment begins after return of spontaneous circulation, the better the therapeutic prospects for the subject at risk of post-resuscitation syndrome. Treatment options and/or the substance to be filtered may also depend upon the timing of treatment. For example, treatment within 1 hour of cardiac arrest or cessation of circulatory function may comprise removal of white blood cells which secret toxic enzymes into the blood stream. Treatment within 24 h of cardiac arrest or cessation of circulatory function may comprise removal of one or more toxic enzymes and/or free radicals, which result from multifocal hypoxia and microcirculatory dysfunction that occur during this period. Treatment and/or prevention may begin, however, prior to cardiac arrest, ischemia, or similar event.
- Methods of treatment may also begin at 0 to 20 minutes, at 20 minutes to 6 hours, at 72 hours, etc., from return of spontaneous circulation (ROSC).
- treatment methods include induction of hypothermia
- body temperature is generally reduced soon after ischemia/surgery/loss of spontaneous circulation, e.g., within 1 hour, 45 minutes, 30 minutes, 25 minutes, 15 minutes or even 1 minute.
- treatment methods include induction of hypothermia
- body temperature reduction may also be induced upon return of spontaneous circulation, e.g., immediately after return of spontaneous circulation, within 0-5 minutes, 6-20 minutes, 21-45 minutes, or 46-60, or 90 minutes of return of spontaneous circulation.
- Hypothermia may be induced, for example, via infusion of cold saline, with ice bags, or by other conventional methods.
- Treatments may be administered in a single session or in multiple sessions.
- Subjects to be treated are not particularly limited.
- Subjects include patients who have experienced cardiac arrest, post-cardiac arrest brain injury, post-cardiac arrest myocardial dysfunction, systemic ischemia/reperfusion response, or persistent precipitating pathology such as cardiovascular disease, pulmonary disease, CNS disease, infection, hemorrhage, dehydration, etc.
- Subjects include any mammal having or at risk of having PRS, e.g., human subjects.
- the blood circuit formed during the filtration process may be arterio-venous, whereby blood flows from an artery through a large bore cannula into tubing, proceeds through a filter, and returns from the filter to a vein.
- the blood circuit may be veno-venous such that blood flows from a vein to the filter and returns from the filter to a vein.
- Ultrafiltrate may collect in a filter jacket, drained through an ultrafiltrate line, discarded, and/or recycled either into the blood circuit or elsewhere.
- Blood flow may return to the patient at the wrist or radial artery or vein. Blood flow may also return to the patient at a femoral artery or vein access point, e.g., at the inner thigh near the groin.
- the invention provides methods of treating or preventing post-resuscitation syndrome comprising optional induction of hypothermia in a subject.
- the induction of hypothermia may be therapeutic.
- the induction of hypothermia may, for example, be mild such that a patient's body temperature is reduced to, e.g., 33-36° C., moderate such that a patient's body temperature is reduced to, e.g., 28, 29, 30, 31, or 32° C., or deep such that a patient's body temperature is reduced to, e.g., below 28° C.
Abstract
Provided is a therapeutic device that includes tubing; at least one pump; and a column or filter capable of removing leukocytes, cytokines, and/or other blood components from the blood of a patient to effectively treat or prevent post-resuscitation syndrome. Methods for treating and/or preventing post-resuscitation syndrome that include the use of such a device, or a filter or column capable of selectively removing inflammatory biomarkers, are also provided.
Description
- This application is a Continuation of U.S. application Ser. No. 14/669,930, filed Mar. 26, 2015, which claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 61/972,827, filed Mar. 31, 2014. The disclosures of each of the above-identified applications, including the specification, drawings, and claims, are expressly incorporated herein by reference in their entireties.
- The invention relates to methods of treating or preventing post-resuscitation syndrome (PRS) comprising filtering or removing inflammatory biomarkers and/or other blood components from a subject. The invention also relates to a therapeutic device for treating post-resuscitation syndrome.
- Post-resuscitation syndrome (PRS) describes a complex cascade of physiologic events following a cardiac arrest and/or other loss of circulation that remains difficult to treat. PRS shares much in common with the classic condition of sepsis. PRS is characterized by hyperthermia, hypotension, and multiple organ failure (Laurent, J. Am. Coll. Cardiol. 46(3):432-37, 2005, which is incorporated by reference herein in its entirety). PRS is also known as post-cardiac arrest syndrome because the term post-resuscitation implies that the act of resuscitation is complete (Nolan et al., Resuscitation 79:350-379, 2008, which is incorporated by reference herein in its entirety). However, the more complex phase of resuscitation begins after patients regain spontaneous circulation. Id.
- PRS includes the following pathophysiological processes: (1) post-cardiac arrest brain injury, (2) post-cardiac arrest myocardial dysfunction, and (3) systemic ischemia/reperfusion response. (Nolan et al., Resuscitation 79:350-379, 2008). Of course, the syndrome is generally further complicated by the original pathological factors that lead to the initiating cardiac arrest (Nolan et al., Resuscitation 79:350-379, 2008).
- Post-cardiac arrest brain injury may result in impaired cerebrovascular autoregulation, cerebral edema, and/or post-ischemic neurodegeneration. Clinical manifestations include coma, seizures, myoclonus, cognitive dysfunction, persistent vegetative state, secondary Parkinsonism, cortical stroke, spinal stroke, and brain death (Nolan et al., Resuscitation 79:350-379, 2008).
- Post-cardiac arrest myocardial dysfunction may result in global hypokinesis (myocardial stunning), reduced cardiac output, and acute coronary syndrome. Clinical manifestations include early revascularization of acute myocardial infarction, hypotension, dysrhythmias, and cardiovascular collapse (Nolan et al., Resuscitation 79:350-379, 2008).
- Systemic ischemia/reperfusion response may result in systemic inflammatory response syndrome, impaired vasoregulation, increased coagulation and/or coagulation abnormalities, adrenal suppression and/or dysfunction, impaired tissue oxygen delivery and utilization, and impaired resistance to infection. Clinical manifestations include ongoing tissue hypoxia/ischemia, hypotension, cardiovascular collapse, pyrexia (fever), hyperglycemia, multi-organ failure, and infection (Nolan et al., Resuscitation 79:350-379, 2008).
- PRS has also been associated with complement activation, improper regulation of cytokine production by leukocytes, expression of adhesion molecules, cytokine release, and endotoxin presence in plasma (Laurent et al., J. Am. Coll. Cardiol. 46(3):432-37, 2005; and Adrie et al., Curr. Opin. Crit. Care 10:208-212, 2004, which is incorporated herein by reference in its entirety).
- There is a high mortality rate for patients who initially achieve return of spontaneous circulation, which mortality rate is attributed to a pathophysiological response involving the immune system and multiple organs (Nolan et al., Resuscitation 79:350-379, 2008). Indeed, PRS is characterized by a large inflammatory response that has been linked to increased oxidative stress which can lead to nerve cell malfunction or death and subsequently poor outcomes for patients.
- For example, the release of oxygen free radicals, coagulation factors, complement-activation products, and cytokines may occur during revascularization after ischemia (reperfusion syndrome). Previous studies have shown that non-survivors of cardiac arrest have a significantly greater escalation of these pro-inflammatory biomarkers as compared to survivors (Adrie et al., Circulation 106:562-568, 2002; Sipos et al., Resuscitation 81:603-608, 2010, which documents are incorporated by reference herein in their entireties). Moreover, the release of these factors leads to marked activation of neutrophils with up-regulation of their surface adhesion molecules (Adrie et al., Curr. Opin. Crit. Care 10:208-212, 2004). The resulting leukocyte adhesion is an important step in vascular endothelium injury, leading to increased microvascular permeability and thrombosis. Id. The elevation of circulating pro-inflammatory as well as immunomodulatory cytokines and adhesion molecules is a feature of PRS, which mimics the immunological disorders observed in sepsis.
- PRS treatment is time sensitive, and care of PRS patients must accommodate a range of patients, for example, patients who are hemodynamically stable as well as unstable and/or comatose patients. The phases of PRS/post-cardiac arrest syndrome may be categorized as set forth in the following table:
-
TABLE 1 Phases of Post-Cardiac Arrest Syndrome* Phase Description Immediate 0-20 min within the return of spontaneous circulation (ROSC) Early 20 min to 6-12 h Intermediate 6-12 h to 72 h Recovery 72 h to disposition Rehabilitation post-disposition *Source: Nolan et al., Resuscitation 79: 350-379, 2008. - Others have noted that within the first 24 hours after the cardiac arrest or ischemic event, multifocal hypoxia leads to microcirculatory dysfunction, resulting in rapid release of toxic enzymes and free radicals into the blood (Adrie et al., Circulation 106:562-568, 2002). Over the next 1 to 3 days, cardiac function and systemic function improve, but intestinal permeability also increases, which may lead to sepsis and/or multiple organ dysfunction. Id. Days after cardiac arrest serious infection may occur and/or the patient may decline rapidly and die. Id.
- Therapeutic hypothermia after ventricular fibrillation cardiac arrest improves neurologic outcome and has been recommended for post-resuscitation care. Therapeutic hypothermia was thought to benefit patients because the cooling of the body would reduce the amount of the pro-inflammatory substances circulating in the cardiovascular system. However, a recent study in a pig model of cardiac arrest with hypothermia indicates that the inflammatory response still occurs (with corresponding upregulation of markers of systemic inflammation) even when the animals were cooled as early as possible during the arrest (Sipos et al., Resuscitation 81:603-608, 2010).
- Sharp rises in various cytokines and soluble receptors occur in the bloodstream as early as 3 hours after cardiac arrest. Several cytokines, including IL-6, show greater elevation in nonsurvivors than in survivors as well as in patients requiring vasopressor therapy compared with other patients (Adrie et al., Curr. Opin. Crit. Care 10:208-212, 2004).
- However, cytokines and other blood components may be difficult to remove from the blood, especially in a short period of time following loss of circulation/cardiac arrest. For example, cytokines and other toxins are often bound to the blood protein albumin, and conventional dialysis membranes do not remove substantial quantities of these protein-bound toxins from the blood. This is because protein-impermeable membranes are generally used in dialysis methods. Consequently, extracorporeal circuits such as continuous renal replacement therapies (CRRT), coupled plasma filtration adsorption (CPFA) and continuous veno-venous hemodiafiltration (CVVHDF) have been developed to minimize cell-associated cytokine concentrations in the blood of septic patients. However, most extracorporeal circuits to date function primarily as artificial kidneys or perfusion devices.
- There remains a need for treatment methods that filter harmful substances from the blood of a subject post-cardiac arrest and for methods of treating or preventing PRS in subjects having, or at risk of having, PRS. There also remains a need for a device capable of selectively removing blood components for the effective prevention and/or treatment of PRS.
- Accordingly, there is provided a therapeutic device comprising tubing; at least one pump; and a column or filter configured to selectively remove leukocytes, cytokines, and/or other blood components from the blood of a patient having or at recognized risk of having PRS at a blood flow rate through the filter or column of at least 2.5 L per hour to effectively treat or prevent PRS. The therapeutic device may optionally comprise a blood temperature regulator.
- There is also provided such a device comprising a column or filter that is capable of removing interleukins, tumor necrosis factor α (TNF-α), c-reactive protein (CRP), nuclear factor-kappa B (NF-κB) subunit p65, interferon-γ, elastase, inducible NO synthase, heme oxygenase-1, free radicals, intracellular adhesion molecules, vascular cell adhesion molecule-1, complement components, granulocyte-macrophage colony-stimulating factor (GM-CSF), monocyte chemoattractant protein-1 (MCP-1), Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) protein, and/or von Willibrand factor (VWF). The interleukins include, for example, IL-1β, IL-2, IL-4, IL-6, IL-10, and IL-15. The intracellular adhesion molecules include ICAM1, ICAM2, ICAM3, ICAM4, and ICAM5. The free radicals are not limited and may be, for example, free iron radicals or free oxygen radicals. The complement components include, for example, C3a and terminal complement complex (TCC).
- In an embodiment, the device may selectively remove IL-6.
- In an embodiment, the device may be portable.
- In an embodiment, the device may be configured for a blood filtration rate of 2.5-5 L/hr.
- There is also provided a device as described above, wherein the filter or column comprises a hydrogel layer to which one or more molecules capable of selectively binding leukocytes, cytokines, and/or other blood components has been immobilized. In an embodiment, the hydrogel comprises dextran.
- The invention also provides a therapeutic device as described above which comprises a surface treatment filter.
- There is also provided a therapeutic device comprising tubing, at least one pump, a blood temperature regulator, and a column or filter, wherein the device is capable of detecting the presence and/or amount of soluble PRS-inducing or -exacerbating blood components, and selectively removing or partially removing one or more of the detected blood components from the blood of a subject.
- The invention also provides such a device further comprising one or more of an air-free pressure chamber, a pressure sensor, an oxygenator, a blood leak detector, an air detector, a cooler, a heater, an LED touch screen, and/or a battery.
- In an embodiment, the LED touch screen displays information relating to the nature and/or amount of one or more PRS-inducing or -exacerbating blood components in the blood to be filtered. For example, the LED touch screen may display information relating to IL-6 plasma concentration levels. The device may also be configured to detect and display information about the nature and/or amount of the one or more PRS-inducing or -exacerbating blood components in the blood to be filtered within about 45 minutes or less after filtration has started. The device may also be configured to detect and display information about the nature and/or amount of the one or more PRS-inducing or -exacerbating blood components in the blood to be filtered in 30 minute intervals and to adjust flow rate through the filter or column based on the information.
- In an embodiment, the device may be configured to increase flow rate through the filter or column when IL-6 plasma concentration levels are detected above 200 μg/L after 45-75 minutes after filtering with the device.
- There is also provided such a device in which the LED touch screen displays information relating to the nature and/or amount of one or more PRS-inducing or -exacerbating blood components in the blood post-filtration.
- There is also provided a device as described above, which adjusts flow rate through the filter or column to maintain IL-6 plasma concentration levels below 200 μg/L in post-filtration blood.
- In an embodiment, the therapeutic device of the present invention may be configured to induce therapeutic hypothermia in the subject.
- The device of the present invention may also be configured for automated plasma recovery and pressure-driven automatic flow control.
- In an embodiment, the filter or column may be present as part of a detachable filtration module. The detachable module may be exchanged or selected for insertion in the device depending upon the blood component or blood components to be removed.
- In another aspect, there is also provided a therapeutic device for filtering blood comprising a pump, and a filtering module comprising one or more cylinders and filter material on at least a partial inner surface of the one or more cylinders, the therapeutic device being configured to send blood into and/or through the one or more cylinders along a spiral path such that blood components that induce or exacerbate PRS in a subject, or a portion thereof, are selectively retained in the one or more cylinders. Such a device, may for example, slowly inject blood in an upward direction combined with a fast rotary motion to exert a centrifugal force on the blood sent into and/or through the one or more cylinders, such that one or more of the blood components that induce or exacerbate PRS in a subject contact the filter material. In an embodiment, the therapeutic device may be configured to obtain a centrifugal force within the one or more cylinders of 10,000 to 100,000 G.
- In another system, biocompound-specific adhesion is used to filter the blood, rather than a size-based pore filtration. In one embodiment, a spiral-wound filter is constructed to provide a compact filter with a large surface area over which the blood is flowed. The filter is made up of an outer housing in which the blood is contained, composed of a cylinder side wall and two end caps (
FIG. 5A ). Inside the housing is the filter element (FIG. 5B ), whose filter inlet port and exhaust port protrude through the walls of the end caps via sealed holes. The blood flows in a spiral fashion from the fluid inlet port into the inner tube then into the spiral space via the inlet exhaust ports. The blood flows in a spiral fashion within the spiral space and because of the spiral shape, the blood is exposed to a very large surface area. So, for instance, for a filter diameter of 6 inches and a length of 6 inches and a spacing between the layers in the spiral of 0.2 inches, the surface area of blood/filter contact is 900 square inches. The filter element is a laminate structure of a substantially impermeable, flexible but semi-rigid substrate support layer, of a relatively blood-inert composition such as polyethylene or cellulose. Laminated to that surface is the active surface matrix, in some cases made of carboxymethyl dextran to which molecules can be covalently attached using well-defined chemistries (see Lofas S, Johnsson B, J. Chem. Soc. Chem. Commun. 21:1526-1528, 1990). The dextran layer creates a suspended hydrogel that is conducive to adhering blood agents. In general, the carboxymethyl dextran minimizes nonspecific binding of biomolecules to the surface and increases the binding capacity of the surface. The surface chemistry of the dextran may be modified to provide a surface with altered properties such as hydrophobic, lipophylic, or lower charge. - A pliant over-molded sealing and spacing ridge is over-molded onto the perimeter of the laminate structure such that when it is wound around the inner tube, it provides multiple sealing functions: 1) it seals against the inner tube; 2) it seals against the adjoining layers at the two ends so that blood fluid is forced to flow only spirally; 3) it seals against the outer tube; and when the filter element is placed into the cylinder side wall and the two end caps are placed and compressed into position before being glued or ultrasonically welded to the cylinder side wall, they seal against the end caps and side wall.
- As described, for instance, in Yang et al., Lab Chip 5:1017-1023, 2005, the surface is functionalized to adhere to PRS-inducing or -exacerbating blood components. For instance, for IL-8 specific adhesion, “two monoclonal antibodies recognizing different epitopes of IL-8” may be used. “MAB208 is a mouse immunoglobulin G1 (IgG1) that was raised against human IL-8 and then protein G column purified from mouse ascites fluid by R & D Systems (Clone No. 6217.111; Cat. No. MAB208). JK8-2 is a mouse IgG1 that was raised against human IL-8 and produced by Biolegend (San Diego, Calif.; Clone No. JK8-2; Cat. No. 508502). It was purified by protein G affinity chromatography and then biotinylated. As a polishing step, size-exclusion chromatography (Amersham FPLC with a Superdex-200 gel filtration column) was applied by our laboratory to eliminate traces of other proteins such as albumin from both monoclonal antibodies. The antibody fractions were collected in HBS-EP buffer and concentrated with Amicon Ultra Centrifugal Filter Devices (10 kDa) from Millipore (Billerica, Mass.; Product No. UFC901024). The purity was determined by SDS-PAGE and MALDI-TOF mass spectroscopy. The concentrations were measured using a Micro BCA Protein Assay Kit from Pierce (Rockford, Ill.; Cat. No. 23235).” Id. Other monoclonal antibodies may be used to bind to one or more of these PRS-inducing or -exacerbating blood components.
- Alternatively, the surface matrix may be functionalized to adhere to free iron in the bloodstream. Free iron, typically in the form of Fe3+, can be captured by iron-binding compounds such as siderophores that may be used to functionalize the surface of the surface matrix. Siderophores are iron-complexing compounds of low molecular weight that are synthesized by bacteria and fungi, and serve to deliver the iron to the microbes. Ferriooxamine is one example. Siderophores are classified into five principal groups according to their chemical structures: hydroxamates, catecholates, carboxylates, heterocyclic compounds, and mixed types. All the natural siderophores are designed to chelate (adhere to) Fe(III) selectively (Reference: Inorganic Biochemistry of Iron Metabolism, Robert Crichton, 2001, Wiley and Sons).
- The blood is circulated in the spiral fashion in the spiral space of the filter element, flowing outwardly until it reaches the exit intake ports of the outer tube, through which the blood exits into the outer tube and finally out the exhaust port. The device may employ pressure at the inlet port as well as negative pressures at the exhaust port. The filter may be alternatively configured to have the blood flow spirally inward toward the central tube, in which case the center tube becomes the exhaust port and the outer tube becomes the intake port. The surface matrix may be composed of alternative materials such as spun polyethylene teraphthalate (PET), cellulose acetate, polyurethanes, nylon, polyacrylonitrile or polypropylene.
- The semi-rigid substrate may be formed into the cylindrical spiral shape by creating features on the inner tube that the over-molded ridge to which the in-most edge of the semi-rigid substrate is affixed and then winding the semi-rigid substrate around the inner tube as a mandrel. The semi-rigid material may be a polymer that can be thermoformed and the material can be heated to soften it while the winding is occurring. The inner mating surface of the end caps into which the filter element seats may be conically shaped so that when all the components are pressed together for the final assembly, the inner wall of the end caps press inward on the over-molded sealing edge at the top and bottom of the filter element, thus sealing the end-surfaces of the filter element. In order to improve sealing, the ends of the filter element may also be sealed with a non-bioactive sealing agent like silicone.
- The flexible semi-rigid support layer should have both a smooth surface and preferably a surface that may be treated with a material of low binding force to the blood so that it is conducive for maximal laminar flow along the surface of the semi-rigid support layer. On the other hand, the surface matrix will be roughened which will result in turbulent, non-laminar flow along its surface. These two surface properties will result in the blood having different velocities relative to the inner and outer regions of the blood volume. This differential velocity will cause a rolling-mixing action of the blood volume, thereby causing enhanced contact of all the blood volume with the activated surface matrix, and further enhancing the removal of the agents.
- There is also provided a filter or column comprising a filter material capable of removing leukocytes and/or soluble blood components from the blood of a subject having or at recognized risk of having PRS at a blood flow rate through the filter of at least 2.5 L per hour to effectively treat or prevent PRS. The filter or column may selectively remove cytokines from the blood.
- There is also provided a system for determining a treatment procedure for a subject having or at recognized risk of having PRS comprising a module for obtaining a blood sample from the subject; a module for measuring and/or identifying the presence, absence, or amount of one or more biomarkers present in the blood of the subject after cardiac arrest, ischemia or other loss of circulation; a module and LED screen capable of determining and displaying a treatment procedure for the subject based on the presence, absence, or amount of the measured and/or identified one or more biomarkers; and an adjustable filter module.
- The present invention also provides a method of treating or preventing PRS comprising filtering blood of a subject having or at recognized risk of having PRS with a device a described above.
- There is also provided a method of treating or preventing PRS comprising passing the blood of a subject at risk of PRS through a device configured to remove leukocytes, cytokines, free radicals, von Willibrand factor, and/or other blood components at a flow rate of at least 2.5 L per hour to effectively treat or prevent PRS. In an embodiment, there is also provided such a method wherein an anticoagulant, a chelating agent, and/or a glucocorticoid is added to the blood as it passes through the device. The anticoagulant may be Anticoagulant Citrate Dextrose Solution A (ACD-A) or heparin. There is also provided such a method, wherein the device is configured for extracorporeal blood circulation. For example, the method may comprise filtering the blood extracorporeally to remove leukocytes. The leukocytes to be removed may be lymphocytes, granulocytes and/or monocytes. In an embodiment, the method comprises partial removal of peripheral neutrophils.
- There is also provided a method of treating or preventing PRS comprising inducing hypothermia in a subject at risk of PRS, and passing blood of a subject at risk of PRS through a device as described above.
- In an embodiment, there is also provided a cylindrical filter element comprising a surface activated fiber sheet and a substrate support that form a layer, the layer wound in a spiral about an inner tube; and a space adjacent to at least a partial surface of the fiber sheet, the filter element being configured to accommodate blood flow in a spiral path and to allow blood to come into contact with the fiber sheet such that blood components that induce or exacerbate PRS in a subject, or a portion thereof, are selectively retained in the filter element. In an embodiment, such a cylindrical filter element may comprise a flexible semi-rigid support layer having a smooth surface and a surface treated with a material of low binding force in the blood. In an embodiment, such a cylindrical filter element may comprise a roughened surface matrix for turbulent, non-laminar flow along its surface.
- In an embodiment, there is provided a therapeutic device comprising a filter element comprising a surface activated filtering agent that attracts free iron, and which is configured to selectively remove the free iron from the blood of a patient having or at recognized risk of having PRS at a blood flow rate through the filter element of at least 2.5 L per hour to effectively treat or prevent PRS.
- In an embodiment, there is provided a filter element comprising a filter material having an enhanced surface area for efficient and selective removal of one or more PRS-inducing or -exacerbating blood components from the blood of a patient having or at recognized risk of having PRS at a blood flow rate through the filter element of at least 2.5 L per hour to effectively treat or prevent PRS. In an embodiment, the filter element may comprise carbon nanofibers or sintered nanoparticles. In an embodiment, the surface area of the filter material may be enhanced by chemical vapor deposition.
- In another embodiment, there is provided a method of making a filter element with an enhanced surface area, the method comprising obtaining a filter material capable of removing leukocytes and/or soluble blood components from the blood of a subject having or at recognized risk of having PRS at a blood flow rate through the filter element of at least 2.5 L per hour to effectively treat or prevent PRS, and coupling nanofibers to the filter material or sintering nanoparticles to the filter material.
- In another embodiment, there is provided a method of making a filter element with an enhanced surface area, the method comprising obtaining a filter material capable of removing leukocytes and/or soluble blood components from the blood of a subject having or at recognized risk of having PRS at a blood flow rate through the filter element of at least 2.5 L per hour to effectively treat or prevent PRS, and exposing the filter material to chemical vapor deposition.
-
FIG. 1 shows a portable device capable of removing leukocytes, cytokines, and/or other blood components from the blood of a patient to effectively treat post-resuscitation syndrome. -
FIG. 2 shows a cylindrical column for filtering blood of a subject that has or is at risk of having post-resuscitation syndrome. -
FIG. 3A shows a filter module for filtering blood of a subject that has or is at risk of having post-resuscitation syndrome. -
FIG. 3B shows three possible membranes that may be included in the filter module for removing one or more types of cells and/or other blood components. -
FIG. 4A provides a partial view of a conical-shaped cylinder having an inner surface comprising a membrane filter or surface treatment filter. -
FIG. 4B shows a detachable filter module comprising multiple conical-shaped filters, housing for the filters, and a base. -
FIG. 5A shows the outer housing for a filter element. -
FIG. 5B shows a filter element, which may be placed in an outer housing. -
FIG. 6 shows extracorporeal filtration of IL-6 from a subject. -
FIG. 7 shows a flow diagram for one possible course of treatment or prevention for post-resuscitation syndrome with a device capable of achieving a blood flow rate of at least 2.5 L/h. -
FIG. 8 shows a flow diagram for one possible method for determining a treatment course for post-resuscitation syndrome. - As used herein, the singular forms “a,” “an,” and “the” include the plural reference unless the context clearly dictates otherwise. For example, reference to “a cytokine” would also mean that mixtures of one or more cytokines can be present unless specifically excluded.
- Except where otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not to be considered as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding conventions.
- Additionally, the recitation of numerical ranges within this specification is considered to be a disclosure of all numerical values and ranges within that range. For example, if a range is from about 1 to about 50, it is deemed to include, for example, 1, 7, 34, 46.1, 23.7, or any other value or range within the range.
- The various embodiments disclosed herein can be used separately and in various combinations unless specifically stated to the contrary.
- Device
- A device as invented by the inventors may comprise tubing, at least one pump, and a column or filter capable of selectively removing leukocytes, cytokines, and/or other blood components from the blood of a patient having or at recognized risk of having post-resuscitation syndrome (PRS) to effectively treat or prevent post-resuscitation syndrome. The device may be therapeutic and may function as a device to treat or prevent post-resuscitation syndrome and/or one or more symptoms of post-resuscitation syndrome. For example, the device may be capable of inducing hypothermia in a subject, pump and receive blood from a subject, pump blood from a subject through one or more filter modules, filter blood of a subject to remove toxic substances that cause or exacerbate post-resuscitation syndrome, and/or return the blood of a subject to the subject. The device may function to pump blood extracorporeally, for filtration, heating or cooling, or other treatment.
- In another embodiment, there is provided a therapeutic device comprising tubing, at least one pump, a blood temperature regulator, and a column or filter, wherein the device is capable of detecting the presence and/or amount of soluble PRS-inducing or -exacerbating blood components, and selectively removing or partially removing one or more of the detected blood components from the blood of a subject.
- In an embodiment, there is provided a therapeutic device comprising a pump, and a filtering module comprising one or more cylinders and filter material on at least a partial inner surface of the one or more cylinders, the therapeutic device being configured to send blood into and/or through the one or more cylinders along a spiral path such that blood components that induce or exacerbate PRS in a subject, or a portion thereof, are selectively retained in the one or more cylinders. In such a device, and without being bound to a particular mechanism of operation, centrifugal force is exerted on the blood sent into and/or through the one or more cylinders, such that one or more of the blood components that induce or exacerbate PRS in a subject contact the filter material. The device may, for example, slowly inject blood in an upward direction and simultaneously rotate the fluid contents to exert a centrifugal force on the blood sent into and/or through the one or more cylinders. In this way, the blood contacts the filter material on the inner surface of one or more cylinders and substances that induce or exacerbate PRS are selectively retained while the filtration product returns to the base of the filtration module via gravity, where it may be further circulated back to the subject. Such a device provides rapid and efficient removal and/or retention of selective blood components—even at high blood flow rates through the device. The centrifugal force within one or more cylinders of the device may be 10,000 to 100,000 G; 20,000-80,000 G, 25,000-75,000 G, or 50,000 G.
- In another embodiment, there is provided a device comprising tubing, at least one pump, a blood temperature regulator, and a detachable module capable of removing leukocytes, cytokines, and/or other blood components from the blood of a patient to effectively treat or prevent post-resuscitation syndrome. There is also provided such a device, wherein the detachable module selectively removes cytokines up-regulated during post-resuscitation syndrome. There is also provided such a device wherein the detachable module selectively removes free iron radicals. There is also provided such a device wherein the detachable module may be exchanged or selected for insertion in the device depending upon the blood component to be removed. A cassette tubing system and slide stator pumps may be included and preparation time of the tubing may thereby be reduced. Arterial and venous tubing may be loaded simultaneously, and the use of cassette tubing allows for correct position of air detectors. The slide stator pumps also provide for tubing set up without winding.
- A device as provided herein may be capable of therapeutic apheresis and/or continuous renal replacement therapy. The device may, for example, be capable of automated plasma recovery and/or may have pressure driven automatic flow control. The device may be capable of automatic priming and thereby reduced priming time compared to conventional devices. Reduced priming volumes and increased safety may also be achieved by automatic priming.
- In an embodiment, the device may be high-volume hemofiltration device. The device may achieve blood flow rates of, for example, 1-400 mL/min. In a preferred embodiment, the device may be capable of blood flow rates of 200-400, 300-375, or 350 mL/min.
- In an embodiment, the device is configured to increase flow rate through the filter or column when IL-6 plasma concentration levels, or when the levels of a different cytokine or blood component, are detected above 200 μg/L. The plasma concentration levels are not particularly limited. For example, if IL-6 plasma concentration levels in a subject are above 150-500 μg/L, the device may detect such concentration and adjust the flow rate through the filter or column accordingly. The device may also adjust flow rate through the filter or column to maintain plasma concentration levels of a PRS-inducing or -exacerbating blood component below a certain toxic threshold. For example, the device may be configured to adjust flow rate through the filter or column to maintain IL-6 plasma concentration levels below 150, 175, 190, 200, 210, or 250 μg/L in post-filtration blood.
- Similarly, the timing of such detection and/or filtration/flow rate adjustment is not limited. The device may obtain measurements of blood component levels at any time, including, for example, 45 min, 50 min, 60 min, 65 min, 70 min, or 75 min after collecting a sample from the subject at risk of having or having post-resuscitation syndrome. The device may be further configured to detect levels of blood components such as cytokines, free radicals, etc., at intervals of 10 min, 15 min, 20 min, 30 min., 45 min, and so on.
- The device of the present invention will be capable of a range of blood filtration rates as well. For example, the blood filtration rate of the device as described herein may achieve a blood filtration rate of 0.9 to 10 L/h, 1 to 9 L/h, 2 to 8 L/h, 2.5 to 5 L/h, 3, 4, 6, or 7 L/h.
- In a preferred embodiment, the device may be configured for extracorporeal circulation. The device may be stationary or portable. The portable device may, for example, have wheels, and/or be of light weight and compact, such that it may be conveniently carried, transported, or rolled to a patient at risk of post-resuscitation syndrome.
- Filters and Columns
- The filter of the device is not particularly limited, and may be, for example, selected from commercially available filters, etc. The filter may be, for example, a leukocyte removing filter as described in U.S. Pat. Nos. 8,496,833; 7,641,794; and 7,655,146, each of which is incorporated by reference herein in its entirety. In an embodiment, the filter may be a surface treatment filter.
- Similarly, the column of the device is not particularly limited, and may be a leukocytapheresis column or a commercially available column capable of removing leukocytes.
- One of ordinary skill in the art will appreciate that the filter or column may be selected based on the nature and/or amount of blood components to be removed and/or reduced. Filters and columns of the invention may remove leukocytes, cytokines, and/or other blood components from the blood of a patient to effectively treat or prevent post-resuscitation syndrome. Leukocytes to be removed include, for example, granulocytes (e.g., neutrophils, eosinophils, or basophils), macrophages, monocytes, and/or lymphocytes (e.g., B cells and T cells). Filters and columns of the invention may remove all cells of a certain type or a partial amount. For example, the filters and/or columns of the invention may partially remove peripheral neutrophils from the blood of subject having or at risk of having PRS. Similarly, filters and columns of the invention may remove all cytokines of a certain type or just a partial amount or a percentage of one or more types of cytokine. Cytokines to be removed include any of the cytokines described herein. For example, the filter or column may be configured to reduce soluble IL-6 levels in the blood of a subject by 90%, 75%, 60%, 50%, 40%, etc.
- The column or filter may also be configured to selectively remove free iron, free iron radicals, complement components, von Willebrand factor, free oxygen radicals, etc.
- The column or filter may have a volume of 25-500 mL, 50-300 mL, 100-200 mL, 125-175 mL or 150 mL, and may be in the shape or a cylinder or cone. The column or filter may be 50-600 mm in height, 75-500 mm in height, 100-400 mm in height, 125-350 mm in height, 150-300 mm in height, 175-250 mm in height, 200-225 mm in height, 550, 450, or 375 mm in height. In an embodiment, the device may comprise multiple conical-shaped filters or membranes which selectively retain or exclude blood components based on size, binding capacity of the filter or membrane, or specificity with regard to, for example, cell type, protein charge, or amino acid sequence.
- The column may be 10-220 mm, 20-200 mm, 30-180 mm, 40-160 mm, 50-150 mm, 75-100 mm, 60, 70, 80, 90, 110, 120, 130, 140, 170, or 190 mm in diameter.
- The column or filter may comprise nonwoven fabric, such as nonwoven fabric comprising polyethylene terephthalate. In addition to polyethylene, other materials which may used as part of the column or filter include hydrogels, dextran (e.g., carboxymethyl dextran), cellulose, gold, or glass. The materials may be used alone or in combination. For example, the column or filter may comprise material capable of removing leukocytes and/or soluble blood components from the blood of a subject having or at recognized risk of having PRS at a blood flow rate through the filter of at least 2.5 L per hour to effectively treat or prevent PRS. The material may be such that is capable of, for example, selectively and simultaneously removing 1, 2, 3 or more blood components from the blood of a subject having or at recognized risk of having PRS at a blood flow rate through the filter of at least 1.0 L, 1.5 L, 2.0 L, 2.5 L, 3.0 L, 3.5 L, 4.0 L, 4.5 L, 5.0 L, 10 L or more per hour.
- The column or filter may comprise an enhanced surface area or an enhanced area to dimension ratio. For example, a surface activated filtering agent present in the filter or column may enhance the chemical attraction of the filter or column material to one or more compounds. The surface area of the column or filter may be enhanced by nanofibers such as carbon nanofibers that are coupled to the surface. The high surface area, low density, and high pore volume of such nanofibers increase the functional filtration surface area of the column or filter. The surface area of the filter may also be enhanced by chemical vapor deposition (CVD). For example, a filter material such as carbon nanofibers may be exposed to chemical vapor deposition to yield nanofiber-supported nanoparticles. Alternatively, the surface area may be enhanced by nanoparticles sintered thereto by any process known to those of skill in the art. The blood components may be efficiently and selectively removed from the blood during filtering via such a column or filter having an enhanced surface area.
- The column or filter may selectively remove inflammatory biomarkers from the blood. For example, the column or filter may be specifically adapted to selectively remove cytokines from whole blood, either by direct removal of IL-6 or by removal of cells that produce them. For example, the column or filter may be specifically adapted to selectively remove IL-6 from whole blood, either by direct removal of IL-6 or by removal of white blood cells that produce IL-6.
- The column or filter may also be configured as a module. The module may be detachable. The column or filter may be present as part of a detachable filtration module or separately. In an embodiment, for example, a column for TNF-α may be detachable such that it may be removed from the device, and a filter or column for removing IL-6 may be inserted in its place. In this way, the detachable module may be exchanged or selected for insertion in the device depending upon the blood component or blood components to be removed.
- In one aspect, the column or filter is capable of removing toxins and harmful substances associated with post-resuscitation syndrome, including, but not limited to: interleukins (e.g., IL-1β, IL-2, IL-4, IL-6, IL-10, and IL-15), tumor necrosis factor α (TNF-α), interferon (e.g., interferon-γ), c-reactive protein (CRP), nuclear factor-kappa B (NF-κB) subunit p65, elastase, inducible NO synthase (iNOS), heme oxygenase-1 (HO-1), free radicals (e.g., free iron radicals or free oxygen radicals), intracellular adhesion molecules (e.g., ICAM1, ICAM2, ICAM3, ICAM4, ICAM5), vascular cell adhesion molecule-1, complement components (e.g., terminal complement complex (TCC) or complement components C3a (C3a)), granulocyte-macrophage colony-stimulating factor (GM-CSF), monocyte chemoattractant protein-1 (MCP-1), Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) protein, and von Willibrand factor (VWF). The column or filter may also be configured to remove white blood cells (e.g., lymphocytes, macrophages, monocytes, granulocytes), or substances secreted by any such white blood cells, red blood cells, or platelets. In one embodiment, the filter module or column be configured to specifically remove one substance or molecule from the blood of a subject or configured to remove a combination of the above substances. In another embodiment, removal) of white blood cells may be performed to prevent an increase in the level of products produced or secreted by white blood cells.
- The column, filter, and/or device of the instant invention may be sterilized by any number of methods, e.g., by gamma-ray sterilization, or by contacting the column, filter, and/or device with a sterilization agent, such as alcohol.
- Other Device Components
- The device may comprise one or more pumps. The pump may be any commercially available pump, for example, non-occlusive centrifugal pumps, slide stator pumps, etc. The pump may withdraw blood from the patient and transport it through the device. The invention provides, for example, a device comprising a pump that transports blood through an extracorporeal circuit or sub-circuit, or an infusion pump that delivers anticoagulants, liquid, solutes, substitute blood components, or other substances and compounds to blood. The one or more pumps of the device are not particularly limited. For example, the pump may be a belt-driven pump. The device may also include a syringe pump, stator pump, or other types of pumps suitable for methods as described herein. The pump may also be any pump that provides excellent stability from low to high speeds.
- The tubing may be, for example, arterial and/or venous tubing. The tubing may be made of any suitable material including plastic or rubber.
- The device may comprise a blood temperature regulator for activating a heater or cooler. The heater may be a resistance heater such as a wire coil. The heater may be in the form of a heat-generating surface. The cooler may be in the form of a heat-absorbing surface. The heat absorbing surface will generally comprise a metal foil wrapped around a catheter, typically having an exposed area of at least about 2 cm2. In an embodiment, the cooler may be a thermoelectric cooler. The components of the device, including the blood temperature regulator, cooler, etc., may be configured to induce therapeutic hypothermia in a subject.
- The device may comprise additional components or modules, such as an oxygenator, catheter, blood infuser, temperature sensor, etc. The oxygenator provides oxygenated blood to be returned to the patient's arterial system. The blood infuser may deliver large volumes of plasma substitute, blood substitute, or whole blood, optionally with preservation and or resuscitation cocktails.
- In aspects and/or embodiments, the device may comprise one or more of an air-free pressure chamber, a pressure sensor, a blood leak detector, an air detector, a scale, an LED touch screen, and/or a battery. Among other functions the air-free pressure chamber may minimize contact between air and blood.
- One or more of the components of the device may be heparin bonded.
- A touch screen may display information relating to the nature and/or amount of one or more PRS-inducing or -exacerbating blood components in the blood to be filtered. The touch screen may display information related to, for example, IL-6 plasma concentration levels. The device of the present invention may also be configured to detect and display information about the nature and/or amount of the one or more PRS-inducing or -exacerbating blood components in the blood to be filtered within about 45 minutes, 30 minutes, 25 minutes, 20 minutes, 10 minutes, or less after filtration had started. A device as provided herein may be, for example, configured to detect and display information about the nature and/or amount of the one or more PRS-inducing or -exacerbating blood components in the blood to be filtered in 30 minute, 25 minute, 20 minute, 15 minute, 5 minutes, or 1 minutes intervals. A device as described herein may also adjust flow rates through the filter or column based on the information that is detected and displayed.
- System
- There is also provided a system for determining a treatment procedure for a subject having or at recognized risk of having PRS. The system may comprise one or more of the following: a module for obtaining a blood sample from the subject; a module for measuring and/or identifying the presence, absence, or amount of one or more biomarkers present in the blood of the subject after cardiac arrest, ischemia or other loss of circulation; a module and LED screen capable of determining and displaying a treatment procedure for the subject based on the presence, absence, or amount of the measured and/or identified one or more biomarkers; and an adjustable filter module. The system may be in the form of a kit or other assembly. The system may comprise device components as described herein, which components function in the context of the system to assist in effectively treating or preventing PRS.
- Methods of Treatment and/or Prevention of Post-Resuscitation Syndrome
- The invention provides methods of treating or preventing post-resuscitation syndrome comprising: passing the blood of a subject at risk of post-resuscitation syndrome through a therapeutic device configured to remove leukocytes, cytokines, free radicals, von Willibrand factor, and/or other blood components after cardiac arrest to effectively treat or prevent post-resuscitation syndrome.
- The present invention also provides a method of treating or preventing PRS comprising filtering blood of a subject having or at recognized risk of having PRS with a device a described above.
- There is also provided a method of treating or preventing post-resuscitation syndrome comprising inducing hypothermia in a subject at risk of post-resuscitation syndrome, and passing blood of the subject at risk of post-resuscitation syndrome through a device comprising tubing, at least one pump, a blood temperature regulator, and a column or filter, the device being capable of detecting the presence and/or amount of soluble PRS-inducing or -exacerbating blood components, and selectively removing or partially removing one or more of the detected blood components from the blood of a subject.
- There is also provided a method of treating or preventing post-resuscitation syndrome comprising passing the blood of a subject at risk of post-resuscitation syndrome through a device configured to remove leukocytes, cytokines, free radicals, von Willibrand factor, and/or other blood components at a flow rate of at least 2.5 L per hour to effectively treat or prevent post-resuscitation syndrome.
- Methods as described above may also include addition of an anticoagulant, a chelating agent, and/or a glucocorticoid to the blood as it passes through the device. The anticoagulant may be Anticoagulant Citrate Dextrose Solution A (ACD-A) or heparin.
- Treatment methods may comprise filtering the blood of a subject having or at recognized risk of having PRS with a device comprising tubing, at least one pump, and a filter or column capable of selective removing leukocytes, cytokines, and/or other blood components from the blood of a patient having or at recognized risk of having PRS at a blood flow rate through the filter of at least 2.5 L per hour to effectively treat or prevent PRS. For example, the method may comprise filtering the blood extracorporeally to remove, for example, leukocytes. The leukocytes to be removed may be lymphocytes, granulocytes and/or monocytes. In an embodiment, the method comprises partial removal of leukocytes (e.g., lymphocytes or peripheral neutrophils), or partial removal of one or more cytokines (e.g., IL-4 or IL-6).
- There is also provided a method of treating or preventing post-resuscitation syndrome comprising inducing hypothermia in a subject at risk of post-resuscitation syndrome, and passing blood of a subject at risk of post-resuscitation syndrome through a device as described above which includes a blood temperature regulator.
- In one aspect of the invention, there is provided a method of treating children after extracorporeal circulation, e.g., for cardiac surgery.
- In another aspect of the invention, there is provided a method of high-volume hemofiltration. High volume hemofiltration may be used to filter large quantities of blood rapidly. For example, high-volume hemofiltration may be used to achieve 100 L of fully balanced ultrafiltration over an 8-hour period. High volume hemofiltration may be performed, for example, at a rate of 180-220 ml/kg/h, 190-210 ml/kg/h, and preferably at 195-205 ml/kg/h. For example, high volume hemofiltration may be performed at 200 ml/kg/h for 8 hours. High volume hemofiltration may also be performed for 0.5-12 h, 1-10 h, 2-9 h, 3-8 h, 4-6 h, or for 5 h. There is also provided similar methods of high-volume ultrafiltration.
- High volume hemofiltration may be performed with or without inducing hypothermia in the subject. Induction of hypothermia may control inflammatory processes and improve recovery and/or survival. Body temperature may be reduced to a desired temperature or range, e.g., 32-36° C., 33-35° C., or 34° C.
- Timing of Treatment and/or Prevention
- The timing and manner of treatment may vary depending upon several factors. Generally the sooner treatment begins after return of spontaneous circulation, the better the therapeutic prospects for the subject at risk of post-resuscitation syndrome. Treatment options and/or the substance to be filtered may also depend upon the timing of treatment. For example, treatment within 1 hour of cardiac arrest or cessation of circulatory function may comprise removal of white blood cells which secret toxic enzymes into the blood stream. Treatment within 24 h of cardiac arrest or cessation of circulatory function may comprise removal of one or more toxic enzymes and/or free radicals, which result from multifocal hypoxia and microcirculatory dysfunction that occur during this period. Treatment and/or prevention may begin, however, prior to cardiac arrest, ischemia, or similar event. Methods of treatment may also begin at 0 to 20 minutes, at 20 minutes to 6 hours, at 72 hours, etc., from return of spontaneous circulation (ROSC). When treatment methods include induction of hypothermia, body temperature is generally reduced soon after ischemia/surgery/loss of spontaneous circulation, e.g., within 1 hour, 45 minutes, 30 minutes, 25 minutes, 15 minutes or even 1 minute. When treatment methods include induction of hypothermia, body temperature reduction may also be induced upon return of spontaneous circulation, e.g., immediately after return of spontaneous circulation, within 0-5 minutes, 6-20 minutes, 21-45 minutes, or 46-60, or 90 minutes of return of spontaneous circulation. Hypothermia may be induced, for example, via infusion of cold saline, with ice bags, or by other conventional methods.
- Duration and Manner of Administration
- Treatments may be administered in a single session or in multiple sessions.
- Subjects to be treated are not particularly limited. Subjects include patients who have experienced cardiac arrest, post-cardiac arrest brain injury, post-cardiac arrest myocardial dysfunction, systemic ischemia/reperfusion response, or persistent precipitating pathology such as cardiovascular disease, pulmonary disease, CNS disease, infection, hemorrhage, dehydration, etc. Subjects include any mammal having or at risk of having PRS, e.g., human subjects.
- The blood circuit formed during the filtration process may be arterio-venous, whereby blood flows from an artery through a large bore cannula into tubing, proceeds through a filter, and returns from the filter to a vein. Alternatively, the blood circuit may be veno-venous such that blood flows from a vein to the filter and returns from the filter to a vein. Ultrafiltrate may collect in a filter jacket, drained through an ultrafiltrate line, discarded, and/or recycled either into the blood circuit or elsewhere. Blood flow may return to the patient at the wrist or radial artery or vein. Blood flow may also return to the patient at a femoral artery or vein access point, e.g., at the inner thigh near the groin.
- Optional Induction of Hypothermia
- The invention provides methods of treating or preventing post-resuscitation syndrome comprising optional induction of hypothermia in a subject. The induction of hypothermia may be therapeutic. The induction of hypothermia may, for example, be mild such that a patient's body temperature is reduced to, e.g., 33-36° C., moderate such that a patient's body temperature is reduced to, e.g., 28, 29, 30, 31, or 32° C., or deep such that a patient's body temperature is reduced to, e.g., below 28° C.
- The particulars shown herein are by way of example and for purposes of illustrative discussion of embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the present invention. In this regard, no attempt is made to show structural details of the present invention in more detail than is necessary for the fundamental understanding of the present invention, the description is taken with the drawings making apparent to those skilled in the art how the forms of the present invention may be embodied in practice.
Claims (35)
1-45. (canceled)
46. A method for treating or preventing ischemia in a subject, comprising:
removing blood from a subject, comprising moving the blood from the subject through a first portion of a circuit comprising a first portion of tubing;
passing the removed blood from the first portion of the circuit through a filter at a blood flow rate of 4-24 L per hour to selectively remove blood components comprising one or more of: leukocytes, cytokines, interleukins, tumor necrosis factor α (TNF-α), c-reactive protein (CRP), nuclear factor-kappa B (NF-KB) subunit p65, interferon-γ, elastase, inducible NO synthase, heme oxygenase-1, free radicals, intracellular adhesion molecules, vascular cell adhesion 55 molecule-I, complement components, granulocyte-macrophage colony-stimulating factor (GM-CSF), monocyte chemoattractant protein-I (MCP-1), Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) protein, and von Willibrand factor (VWF); and
returning the filtered blood to the subject, comprising passing the filtered blood to the subject via a second portion of the circuit comprising a second portion of tubing.
47. The method of claim 46 , wherein the selectively removing the blood components comprises removing the interleukins comprising at least one of IL-1β, IL-2, IL-4, IL-6, IL-10, and IL-15.
48. The method of claim 46 , wherein the selectively removing the blood components comprises removing the intracellular adhesion molecules comprising at least one of ICAM1, ICAM2, ICAM3, ICAM4 and ICAM 5.
49. The method of claim 46 , wherein the selectively removing the blood components comprises removing free radicals comprising at least one of free iron radicals and free oxygen radicals.
50. The method of claim 46 , wherein the selectively removing the blood components comprises removing complement components comprising at least one of C3a and terminal complement complex (TCC).
51. The method of claim 46 , wherein the removing of the blood from the subject comprises using a catheter inserted into the patient's body for use in carrying extracting the blood.
52. The method of claim 46 , comprising oxygenating the blood prior to returning the filtered blood to the subject.
53. The method of claim 52 , comprising oxygenating the blood using an oxygenator in supplying oxygen to be added to the blood.
54. The method of claim 52 , wherein the method is used to treat ischemia.
55. The method of claim 54 , wherein the method is used to treat ischemia following a heart attack.
56. The method of claim 54 , wherein the method used to treat ischemia following a cardiac arrest.
57. The method of claim 52 , wherein the method is used to treat one or more of post-cardiac arrest brain injury, post-cardiac arrest myocardial dysfunction, reperfusion response, persistent pathology, cardiovascular disease, pulmonary disease, CNS disease, infection, hemorrhage, and dehydration.
58. The method of claim 52 , wherein the selectively removing the blood components comprises removing free radicals.
59. The method of claim 52 , wherein the selectively removing the blood components comprises removing oxygen free radicals.
60. The method of claim 52 , wherein the selectively removing the blood components comprises removing heme oxygenase-1.
61. The method of claim 52 , wherein passing of the removed blood through the filter comprises passing the removed blood through a therapeutic device comprising the filter, and wherein the circuit connects the device and the subject.
62. The method of claim 70 , wherein passing of the removed blood through the filter comprises passing the removed blood through the therapeutic device, wherein the therapeutic device displays information on a screen.
63. The method of claim 71 , wherein the therapeutic device comprises a wherein passing of the removed blood through the filter comprises passing the removed blood through the therapeutic device, wherein the therapeutic device displays information on a touch screen.
64. The method of claim 52 , wherein the moving of the blood comprises using at least one pump for pumping the blood.
65. The method of claim 52 , comprising, prior to the removing of the blood from the subject, inducing therapeutic hypothermia of the subject.
66. The method of claim 52 , comprising inducing therapeutic hypothermia of the subject by returning cooled blood to the subject.
67. The method of claim 52 , comprising using a blood temperature regulator in inducing therapeutic hypothermia of the subject by returning cooled blood to the subject.
68. The method of claim 52 , comprising selectively removing the blood components comprising at least one of soluble or secreted blood components.
69. The method of claim 68 , comprising the passing of the removed blood through the filter, wherein the filter comprises a hydrogel layer to which one or more molecules capable of binding one or more of the blood components has been immobilized.
70. The method of claim 68 , comprising the passing of the removed blood through the filter, wherein the filter comprises a base and one or more conical cylinders with a larger opening of the one or more conical cylinders oriented away from the base.
71. The method of claim 68 , wherein a therapeutic device comprises the filter, and wherein the therapeutic device exerts a centrifugal force on the blood within the one or more conical cylinders, thereby sending the blood into or through the one or more conical cylinders along a spiral path such that the soluble or the secreted blood components, or a portion thereof, are selectively retained in the one or more conical cylinders.
72. The method of claim 46 , wherein the passing of the removed blood from the first portion of the circuit through the filter at the blood flow rate of 4-24 L per hour comprises passing the removed blood from the first portion of the circuit through the filter at a blood flow rate of 4-4.5 L per hour.
73. The method of claim 46 , wherein the passing of the removed blood from the first portion of the circuit through the filter at the blood flow rate of 4-24 L per hour comprises passing the removed blood from the first portion of the circuit through the filter at a blood flow rate of 4-5 L per hour.
74. The method of claim 46 , wherein the passing of the removed blood from the first portion of the circuit through the filter at the blood flow rate of 4-24 L per hour comprises passing the removed blood from the first portion of the circuit through the filter at a blood flow rate of 4-10 L per hour.
75. The method of claim 46 , wherein the method is used to treat or prevent post-resuscitation syndrome (PRS).
76. The method of claim 46 , comprising adjusting flow rate through the filter based on information about a nature or amount of one or more soluble or secreted blood components in the blood.
77. The method of claim 46 , comprising adjusting flow rate through the filter based at least in part on information about a nature or amount of one or more soluble or secreted blood components to be filtered in 30 minute intervals.
78. The method of claim 46 , comprising using pressure-driven automatic flow control in adjusting flow rate through the filter to maintain one or more soluble or secreted blood components in the blood below a toxicity threshold.
79. The method of claim 46 , comprising detecting IL-6 and adjusting flow rate through the filter to maintain IL-6 below a toxicity threshold.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/136,377 US20210283323A1 (en) | 2014-03-31 | 2020-12-29 | Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461972827P | 2014-03-31 | 2014-03-31 | |
US14/669,930 US10905818B2 (en) | 2014-03-31 | 2015-03-26 | Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome |
US17/136,377 US20210283323A1 (en) | 2014-03-31 | 2020-12-29 | Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/669,930 Continuation US10905818B2 (en) | 2014-03-31 | 2015-03-26 | Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210283323A1 true US20210283323A1 (en) | 2021-09-16 |
Family
ID=54188853
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/669,930 Active US10905818B2 (en) | 2014-03-31 | 2015-03-26 | Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome |
US17/136,377 Pending US20210283323A1 (en) | 2014-03-31 | 2020-12-29 | Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/669,930 Active US10905818B2 (en) | 2014-03-31 | 2015-03-26 | Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome |
Country Status (3)
Country | Link |
---|---|
US (2) | US10905818B2 (en) |
JP (3) | JP6728536B2 (en) |
WO (1) | WO2015153287A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10518039B2 (en) | 2016-04-29 | 2019-12-31 | Verily Life Sciences Llc | Apparatus and methods for tracking administering of medication by medication injection devices |
US10688255B2 (en) * | 2016-04-29 | 2020-06-23 | Verily Life Sciences Llc | Air shot detection |
US10953155B2 (en) | 2016-04-29 | 2021-03-23 | Verily Life Sciences Llc | Pressure sensor in plunger head to wake up electronics |
WO2019136289A1 (en) * | 2018-01-05 | 2019-07-11 | Path Ex, Inc. | Device for the capture and removal of disease material from fluids |
US10952758B1 (en) * | 2018-12-20 | 2021-03-23 | Jason M. Evans | Kidney stone turbulent flow irrigator and system |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4033881A (en) * | 1975-01-06 | 1977-07-05 | Pall Corporation | Multilayer paper sheet filter cartridges |
EP0132534B1 (en) * | 1983-06-01 | 1991-07-24 | Kanegafuchi Chemical Industry Co., Ltd. | Device for the extracorporeal treatment of body fluids |
US5137637A (en) * | 1991-06-18 | 1992-08-11 | Exxon Chemical Patents Inc. | Rotational high flux membrane device |
US20050277863A1 (en) * | 2003-03-17 | 2005-12-15 | Davidner Alan A | Device and method for reducing inflammatory mediators in blood |
US20090221514A1 (en) * | 2008-02-26 | 2009-09-03 | Szeto Hazel H | Methods for prevention and treatment of acute renal injury |
US20100217172A1 (en) * | 2009-02-25 | 2010-08-26 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device, system, and method for controllably reducing inflammatory mediators in a subject |
US20120302995A1 (en) * | 2010-02-02 | 2012-11-29 | Pramote Hochareon | Localized Therapy Delivery and Local Organ Protection |
US20130108715A1 (en) * | 2010-03-10 | 2013-05-02 | School Juridical Person Kitasato Institute | Therapeutic Agent and Therapeutic Device for Alleviating Ischemia-Reperfusion Injury |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362406A (en) | 1990-07-27 | 1994-11-08 | Pall Corporation | Leucocyte depleting filter device and method of use |
US5308320A (en) | 1990-12-28 | 1994-05-03 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Portable and modular cardiopulmonary bypass apparatus and associated aortic balloon catheter and associated method |
DE4331358A1 (en) * | 1992-10-12 | 1994-04-14 | Braun Melsungen Ag | Process for the quantitative selective removal or preparation of tumor necrosis factor (TNF) and / or lipopolysaccharides (LPS) from aqueous liquids |
US5571418A (en) | 1993-08-20 | 1996-11-05 | Lee; Patrice A. | Hemofiltration of toxic mediator-related disease |
WO1997002851A1 (en) | 1995-07-10 | 1997-01-30 | Asahi Medical Co., Ltd. | System and treating extracorporeally circulating blood for curing inflammatory diseases |
US5977345A (en) | 1998-03-03 | 1999-11-02 | Virginia Tech Intellectual Properties, Inc | Inside-out crosslinked and commercial-scale hydrogels, and sub-macromolecular selective purification using the hyrdogels |
CA2322000C (en) | 1998-12-24 | 2008-07-29 | Toray Industries, Inc. | Hemocathartic method and hemocathartic column |
WO2002004045A1 (en) | 2000-07-10 | 2002-01-17 | Asahi Medical Co., Ltd. | Blood processing filter |
JPWO2003014394A1 (en) * | 2001-08-03 | 2004-11-25 | 旭メディカル株式会社 | Biocompatibility evaluation method |
SE0201257D0 (en) * | 2002-04-25 | 2002-04-25 | Medical Invest In Sweden Ab | Improved Separation |
RU2255800C1 (en) * | 2003-10-14 | 2005-07-10 | Германов Евгений Павлович | Magnet-governed sorbent and a method for manufacture thereof |
US8038638B2 (en) | 2004-02-23 | 2011-10-18 | Hemolife Medical, Inc. | Plasma detoxification and volume control system and methods of use |
US7615028B2 (en) | 2004-12-03 | 2009-11-10 | Chf Solutions Inc. | Extracorporeal blood treatment and system having reversible blood pumps |
CN101098704B (en) | 2005-01-06 | 2011-07-13 | 旭化成医疗株式会社 | Method of removing leukocyte |
US7655146B2 (en) | 2006-02-20 | 2010-02-02 | Asahi Kasei Medical Co., Ltd. | Method for filtering blood or blood components using leukocyte-removing filter and filter device |
CA2643140C (en) | 2006-02-22 | 2014-12-09 | Henry Ford Health System | System and method for delivery of regional citrate anticoagulation to extracorporeal blood circuits |
JP5227271B2 (en) | 2009-07-27 | 2013-07-03 | 旭化成メディカル株式会社 | System for removing viruses and cytokines from blood |
WO2011068897A1 (en) * | 2009-12-01 | 2011-06-09 | Exthera Medical, Llc | Method for removing cytokines from blood with surface immobilized polysaccharides |
JP2012213635A (en) | 2011-03-31 | 2012-11-08 | Toray Ind Inc | Hollow fiber membrane for removing protein and method for producing the same |
EP2802367A4 (en) * | 2012-01-09 | 2015-12-16 | H David Humes | Cartridge and method for increasing myocardial function |
EP2679302A1 (en) * | 2012-06-28 | 2014-01-01 | Zentrum für biomedizinische Technologie der Donau- Universität Krems | Selective sorption agent for extracorporeal blood purification |
-
2015
- 2015-03-26 US US14/669,930 patent/US10905818B2/en active Active
- 2015-03-26 WO PCT/US2015/022764 patent/WO2015153287A1/en active Application Filing
- 2015-03-26 JP JP2016557644A patent/JP6728536B2/en active Active
-
2020
- 2020-03-04 JP JP2020037255A patent/JP2020096971A/en active Pending
- 2020-12-29 US US17/136,377 patent/US20210283323A1/en active Pending
-
2022
- 2022-05-20 JP JP2022083450A patent/JP2022116119A/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4033881A (en) * | 1975-01-06 | 1977-07-05 | Pall Corporation | Multilayer paper sheet filter cartridges |
EP0132534B1 (en) * | 1983-06-01 | 1991-07-24 | Kanegafuchi Chemical Industry Co., Ltd. | Device for the extracorporeal treatment of body fluids |
US5137637A (en) * | 1991-06-18 | 1992-08-11 | Exxon Chemical Patents Inc. | Rotational high flux membrane device |
US20050277863A1 (en) * | 2003-03-17 | 2005-12-15 | Davidner Alan A | Device and method for reducing inflammatory mediators in blood |
US20090221514A1 (en) * | 2008-02-26 | 2009-09-03 | Szeto Hazel H | Methods for prevention and treatment of acute renal injury |
US20100217172A1 (en) * | 2009-02-25 | 2010-08-26 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device, system, and method for controllably reducing inflammatory mediators in a subject |
US20120302995A1 (en) * | 2010-02-02 | 2012-11-29 | Pramote Hochareon | Localized Therapy Delivery and Local Organ Protection |
US20130108715A1 (en) * | 2010-03-10 | 2013-05-02 | School Juridical Person Kitasato Institute | Therapeutic Agent and Therapeutic Device for Alleviating Ischemia-Reperfusion Injury |
Also Published As
Publication number | Publication date |
---|---|
US20150273129A1 (en) | 2015-10-01 |
JP2020096971A (en) | 2020-06-25 |
JP2022116119A (en) | 2022-08-09 |
US10905818B2 (en) | 2021-02-02 |
JP2017509406A (en) | 2017-04-06 |
WO2015153287A1 (en) | 2015-10-08 |
JP6728536B2 (en) | 2020-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210283323A1 (en) | Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome | |
JP4787468B2 (en) | Selective adsorption device and selective adsorption system | |
US4614513A (en) | Method and apparatus for treatment to remove immunoreactive substances from blood | |
EP1765433B1 (en) | Plasma detoxification and volume control system | |
EP1740209A2 (en) | Method and system to remove soluble tnfr1, tnfr2, and il2 in patients | |
EP3086870B1 (en) | Plasmapheresis device | |
CA1086235A (en) | Continuous removing system of blood substances by extra corporeal circulation | |
EP0074999A1 (en) | Method and apparatus for the treatment of autoimmune and allergic diseases | |
US4639243A (en) | Process and apparatus for obtaining blood plasma | |
US20180169319A1 (en) | Treatment of cancer by manipulating the immune system | |
US20110009796A1 (en) | Method and apparatus for increasing contaminant clearance rates during extracorporeal fluid treatment | |
US20140251917A1 (en) | Method for the treatment of multiple sclerosis | |
US11383015B2 (en) | System and method for plasma purification prior to mononuclear cell collection | |
US9265875B2 (en) | Methods for treating blood composition and function disorders wherein a patient's blood plasma is extracorporeally contacted with donor blood or modified donor blood | |
US20180093032A1 (en) | Targeted apheresis using binding agents or ligands immobilized on membranes | |
US20190125956A1 (en) | Treatment for Athersclerosis | |
US20180036349A1 (en) | Treatment for Chronic Pain | |
JPH01249062A (en) | Outside body circulation circuit | |
JP7163187B2 (en) | Method and apparatus for concentration of immunoglobulins from blood | |
Parker et al. | [42] Low density lipoprotein-pheresis: Selective immunoadsorption of plasma lipoproteins from patients with premature atherosclerosis | |
WO2024015511A1 (en) | Methods and device related to removal of cell-free plasma hemoglobin | |
CN103732271B (en) | Detection and the method and apparatus of the disease such as treatment tumor and virus infection | |
Bronzino et al. | Therapeutic Apheresis and Blood Fractionation | |
WO2011090943A1 (en) | Removal of pathological albumin from a subject's plasma | |
WO2013142449A2 (en) | Treatment for chronic pain syndromes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ZOLL MEDICAL CORPORATION, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FREEMAN, GARY;KAUFMAN, CHRISTOPHER LUKE;SIGNING DATES FROM 20150115 TO 20150120;REEL/FRAME:054766/0610 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |